Official Title of Study : Embrace TDD: Prospective, Multi-Center, Post-Market Study to 
Evaluate Intrathecal (IT) Morphine as an Alternative to Systemic Opi[INVESTIGATOR_887491], Intractable, Non-Malignant Primary Back Pain with or without Leg Pain 
Study ID: [REMOVED]
Date of Document: 26APR2021
Document Type: Study Protocol
Embrace TDD Clinical Investigation Plan  Form  
MDT18026  Version  3.0 Page 1 of 74  
   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Clin
ical Investigation Plan  
Clinical Investigation Plan/Study Title  Embrace TDD: Prospective, Multi -Center, Post -
Market Study to Evaluate Intrathecal (IT) 
Morphine as an Alternative to Systemic Opi[INVESTIGATOR_887492], Intractable, Non-Malignant Primary Back Pain with or without Leg 
Pain  
Clinical Investigation Plan Identifier  MDT18026  
Study Product Name  [CONTACT_887584]™ II infusion system and 
preservative- free morphine sulfate, USP (PFMS) 
and preservative free 0.9% Sodium Chloride 
Injections, USP (for dilution)  
Sponsor/Local Sponsor  Medtronic Neuromodulation  
[ADDRESS_1242209] NE  
Minneapolis, MN [ZIP_CODE] 
[LOCATION_003] 
[PHONE_10075]
Document Version  3.[ADDRESS_1242210].  
Embrace TDD Clinical Investigation Plan  Form  
MDT18026  Version  3.0 Page 3 of 74  
   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Table of Con tents  
1. Investigator Statement ...... .............................................................................................. 2  
Table of Contents  .................................................................................................................... 3  
2. Glossary  ........................................................................................................................... 7  
3. Synopsis  ........................................................................................................................... 9  
4. Introduction  ...... ............................................................................................................. 14 
4.1 Background  .................................................................................................................... 14 
4.1.1  Preclinical Data  ............................................................................................................. 15 
4.1.2  Clinical Data  .................................................................................................................. 15 
4.2 Purpose  ......................................................................................................................... 16 
4.3 Regulatory Study Classification  ..........................................................................................  17 
5. Objectives and/or E ndpoints  . .........................................................................................  [ADDRESS_1242211] Accountability  ...................................................................................................... 26 
8. Study Site Requirements  ..... ........................................................................................... 26 
8.1 Investigator/Investigatio n Site Selection  ............................................................................. [ADDRESS_1242212] Consent  .......................................................................................................  39 
10.16  Medication Compliance  .............................................................................................. 41 
10.17  Assessment of Efficacy  .............................................................................................. 41 
10.17.1  Visual Analog Scale (VAS)  .............................................................................................. [ADDRESS_1242213] Assessment Tool (NOSE)  ................................................. [ADDRESS_1242214] Withdrawal or Discontinuation  ........................................................................  46 
11. Risks and Benefits  ..... ................................................................................................. 47 
11.1  Potential Risks  ................................................................................................................  47 
11.2  Pregnancy Risks  ..............................................................................................................  49 
11.3  Risk Minimization (Control Measures)  .................................................................................  49 
11.4  Potential Benefits  ............................................................................................................  50 
11.5  Risk-Benefit Rationale  ...................................................................................................... 50 
12. Adverse Events and Device Deficiencies  ..... ................................................................  50 
12.1  Definitions / Classifications  ...............................................................................................  [ADDRESS_1242215] Death  .................................................................................................................  53 
13. Data Review Committees ..... ....................................................................................... 54 
14. Statistical Design and Methods ..... ..............................................................................  54 
14.1  General Aspects of Analysis  .............................................................................................. 54 
14.1.1  Sample Size Justi fication  ............................................................................................... 55 
14.1.2  Investigation Site Pooling  .............................................................................................. 56 
14.1.3  Other Specific Considerations  ....................................................................................... 56 
14.1.4  Reports  ......................................................................................................................... 57 
14.2  Demographics  .................................................................................................................  57 
14.3  Primary Objective – Clinical Success at the 6 -Month Visit  ......................................................  57 
14.4  Secondary Objectives  .......................................................................................................  59 
14.4.1  Secondary Objective #1 – VAS Pain Intensity at the 6 -Month Visit  ............................... 59 
14.4.2  Secondary Objective #2 – NOSE Score  .......................................................................... 60 

Embrace TDD Clinical Investigation Plan  Form  
MDT18026  Version  3.0 Page 6 of 74  
   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  14.4.3  Secondary Objective #3 – Systemic Opi[INVESTIGATOR_887493]  ............................................... 61 
14.6  Safety Assessment  ..........................................................................................................  62 
15. Ethics  ..........................................................................................................................  62 
15.1  Statement(s) of Compliance  .............................................................................................. [ADDRESS_1242216] Access to Source Data/Documents ............................................................................  [ADDRESS_1242217] Retention  ............................................................................................................  67 
16.8.1  Investigator Records  ..................................................................................................... 67 
16.8.2  Investigator Reports  ...................................................................................................... 68 
16.9  Publication and Use of Information  .................................................................................... 68 
16.9.1  Publication Committee  ................................................................................................. 68 
16.9.2  Authorship Selection  ..................................................................................................... 69 
16.10  Suspension or Early Term ination  .................................................................................  69 
16.10.1  Study -Wide Termination or Suspension  ........................................................................ 69 
16.10.2  Investigator/Center Termination or Suspension  ........................................................... 69 
17. References  .... .............................................................................................................. 70
18. Appendices  .... ............................................................................................................. 71 
18.1  Appendix A: Additional Information for Sites  .......................................................................  71 
18.2  Appendix B: Institutional Review Boards  ............................................................................. 71 
18.3  Appendix C: Participating Principal Investigators and Institutions  ........................................... [ADDRESS_1242218]  
AE Adverse Event  
BL Baseline Visit  
  
CEC Clinical Event Committee  
CFR Code of Federal Regulation  
CIP Clinical Investigation Plan  (“Protocol”)  
CMM  Conventional Medical Management  
CNS Cent ral Nervous System  
CRF Case Report Form  
CSF Cerebral Spi[INVESTIGATOR_887494] / ICF  Informed Consent  / Informed Consent Form  
ICH-E6 International Conference of Harmonization  (ICH)  
Guideline for Good Clinical Practice (ICH -E6) 
ICMJE  International C ommittee of Medical Journal 
Editors  
IFP Information for Prescribers  
IRB Institutional Review Board  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242219]  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SUD  Substance Use Disorder  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 9 of 74  
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Acronym  Definition  
TDD  Targeted Drug Delivery  
US [LOCATION_002] [of America]  
USP Unites States Pharmacopoeia  
VAS Visual Analog Scale  
 
3. Synopsis  
Title  Embrace TDD:  Prospecti ve, Multi -Center, Post Market Study to 
Evaluate  Intrathecal (IT) Morphine as an Alternative Systemic Opi[INVESTIGATOR_887492], Intractable, Non- Malignant Primary 
Back P ain with or without Leg Pain  
Clinical Study Type  Post -Market  Interventional  
Product Name  [CONTACT_887584]™ II infusion system:  
The Medtronic SynchroMed II i nfusion s ystem consists of an 
implanted infusion pump and catheter, and external components , a 
clinician programmer, refill and catheter access port kits, the Personal 
Therapy Manager® (myPTM™) . SynchroMed II i nfusion s ystem 
components that become commercially available  after the 
commencement of this study may also be used in addition to, or in lieu of, the currently available  components.  
The pharmacological agent used in the study is limited to 
preservative- free morphine sulfate, USP (PFMS) and preservative free 
0.9% Sodium Chloride Injections, USP (for dilution).  
Sponsor  Medtronic Neuromodulat ion 
[ADDRESS_1242220] NE  
Minneapolis, MN [ZIP_CODE] [LOCATION_003] 
[PHONE_10075]  
Indicatio n Under 
Investigation  Use of Intrathecal Drug Delivery System  (IDDS)  to manage subjects 
with chronic, intractable, non -malignant primary back  pain  with or 
without leg pain . 
Investigation Purpose  To assess pain control and opi[INVESTIGATOR_2480] -related side effects foll owing a 
route of delivery change from systemic opi[INVESTIGATOR_887495].  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242221] labeling.  
The pharmacological agent used in the study is limited PFMS and preservative free 0.9% Sodium Chlorid e Injections, USP (for dilution).  
None of the Medtronic products used in this study are investigational . 
Primary Objective  To characterize the proportion  of subjects with Clinical Success at the 
6-Month  Visit  based on changes in pain intensity using the Visual 
Analog Scale (VAS) and changes in opi[INVESTIGATOR_2480] -related side effects using 
the Numerical Opi[INVESTIGATOR_887496] (NOSE) Assessment  Tool.  
Clinical Success is def ined as any of the following (refer to grid below 
with matching numbers) : 
1) Reduced opi[INVESTIGATOR_2480] -related side effects  with equal pain  
2) Reduced pain with equal opi[INVESTIGATOR_2480] -related side effects  
3) Reduced pain and reduced opi[INVESTIGATOR_2480] -related  side effects  
 
Criteria for Cl inical Success  
Change  
from Baseline  
to the 6 -Month Visit   Opi[INVESTIGATOR_2480] -Related Side Effects  
(NOSE ) 
≥20% 
Increase  < ±20% 
Change  ≥20% 
Reduction  
Worse  Equal  Better  Pain Intensity (VAS)  ≥20% 
Increase  
Worse  
      
< ±20% 
Change  
Equal  
    1  
≥20% 
Reduction  
Better  
   2  3 
 
Secondary Objectives  1. To demonstrate pain intensity scores (VAS) at the [ADDRESS_1242222] scores 
(NOSE) from B aseline to the 6 -Month Visit  
3. To characterize the proportion of subjects who eliminate systemic 
opi[INVESTIGATOR_887497] 6 -Month Visit  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 11 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Safety Assessments  To characterize all systemic opi[INVESTIGATOR_208781] -related, device -related, IT 
drug -related, and procedure -related adverse events (AEs), all serious 
adverse events (SAEs) (regardless of relatedness), and device 
deficiencies (DD) for all subjects from enrollment until the subject 
exits.  
Study Desig n The Embrac e TDD study is a prospective, multi -center, post -market 
study. Subjects with chronic, intractable non- malignant primary back 
pain with or without leg pain will be enrolled in the study and will be 
required to attend a minimum of 7 in -office vis its which include: 
Baseline, Intrathecal Trial, Implant, Post -Op, [ADDRESS_1242223] the secondary objective related to pain score.  
Inclusion/Exclusion Criteria  Inclusion Criteria  
A potential subject may be included for participation in the study if 
the subject has/is:  
1. Willing and able to provide a signed and dated (Medtronic and Institutional Review Board  (IRB) approved) Informed Consent 
Form (ICF) and Health Insurance Portability and Accountability Act  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 12 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  (HIPAA ) Authorization Form prior to an y study procedures being 
performed  
2. A candidate per labeling for the IDDS  
3. A diagnosis of chronic , intractable  non- malignant,  primary back 
pain with or without leg , pain treatable with the IDDS  
4. Current daily systemic opi[INVESTIGATOR_887498] > 0 and ≤ 120 Morphine 
Milligram Equivalents (MME)  
5. A Visual Analogue Scale ( VAS) of ≥5 0 mm  for pain intensity at the 
Baseline Visit and/or a Numerical Opi[INVESTIGATOR_887496] (NOSE) 
Assessment Tool ≥ [ADDRESS_1242224] -menopausal or surgically sterile; or be utilizing a medically 
acceptable form of birth control (i.e. a hormonal contraceptive, intra -uterine device, diaphragm with spermicide, or condom with 
spermicide) for the duration of the study  
 
Exclusion Criteria  
A potential subject will be excluded from participating in the study if the subject has/is:  
1. Previously trialed or implanted with an IDDS  
2. Concomitant stimulation device implanted for the treatment of 
pain  
3. Any ongoing health condition that would be expected to interfere with pain and/or quality of life ratings ( i.e. active malignancy, 
other painful  conditions not treatable with IT therapy, etc .) 
4. Psychological or other health conditions, financial and/or legal concerns that would interfere with the subject’s ability to fulfill the requirements of the protocol as per the investigator’s discretion  
5. Subs tance U se D isorder (SUD) within the last 2  years or current 
Medication Assisted Treatment (MAT) for substance use disorder  
6. Currently using cannabinoids  or illicit drugs 
7. History of allergy or significant adverse reaction to morphine per investigator discret ion 
8. Currently participating or plans to partic ipate in another 
investigational study unless written approval is provided by 
[CONTACT_887558]18026  Version  3.0 Page 13 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Study Procedures and 
Assessments Subjects will be considered enrolled at the time they sign the 
informed consent. Subjects will then be required to wean  off all 
systemic opi[INVESTIGATOR_887499] 5 months (with a minimum of a 7 -
day opi[INVESTIGATOR_887500]) prior to initiation of IT therapy.  
Scheduled Visits will include the following: Baseline, IT Trial, Implant, 
Post -Op, 1 -Month, 3- Month, and 6- Month . 
The following  assessments / data will be collected  during the study:  
a. IT PFMS Dose  
b. VAS for pain intensity  
c. NOSE for opi[INVESTIGATOR_2480] -related side effects  
 
 
  
 
 
  
j. Pain Medications  
k. Adverse Events (A E) 
l. Device Deficiencies (DD)  
 Statistics  For the primary objective of Clinical Success, the proportion of 
subjects with Clinical Success at the [ADDRESS_1242225] binomial 95% confidence interval (CI) will be reported.  
 
For the secondar y objective of pain intensity score, a non- inferiority t -
test will be applied; if non- inferi ority is met, a superiority t -test will be 
followed. The pain scores at both the Baseline and 6 -Month Visits as 
well as the change from Baseline to the 6 -Month Visi t will be 
reported.   
 
For the secondary objective of NOSE s core, descriptive statistics 
(mean and standard deviation, etc.) will be used to report the NOSE  
score at B aseline and the [ADDRESS_1242226] binomial two -sided 95% 
CI will be reported .  
 
 
  
 Adverse events and device deficiencies will be summarized u sing 
summary tables displaying the frequency, percentage, relatedness 
and seriousness . 

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 14 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  4. Introduction  
4.1 Background  
Though morphine use has a documented history going back centuries, intrathecal  (IT) use was first 
reported in [ADDRESS_1242227] use of an implanted pump, 
the fixed -rate Infusaid Model 400, for chronic infusion of morphine as a treatment for pain. 2 Continued 
use, the recognized need, and pressure from patient  advocacy groups prompted the Food and Drug 
Administration  (FDA) to publish a request to industry for applications seeking approval for an effective 
treatment for cancer pain. In July 1991, Hikma Maple received New Drug Application (NDA) (N018565) approval for Infumorph (10 mg/mL and 25 mg/mL preservative -free morphine  sulfate).  
In March 1988, Medtron ic, Inc.  obtained Pre -Market Application (PMA) (P860004) approval for 
SynchroMed for the delivery of chemotherapeutic agents (intravascular floxuridine [FUDR], doxorubicin hydrochloride (Adriamycin), bacteriostatic water, physiological saline and/or  hepari n). In July 1991, PMA 
supplement P860004/S001, originally filed in August 1987, was approved expanding the SynchroMed indication to include IT  administration of preservative -free morphine sulfate  (PFMS) for the treatment o f 
chronic intractable pain of malignant origin. In October 1991, the SynchroMed indication was expanded to include chronic intractable pain of non -malignant origin as well. Since the time of these original 
approvals, evidence -based medicine has emerged as a discipline for evaluating safety  and efficacy, 
creating the need for a high level of evidence to ensure coverage and use. Since approval, the management of IT  opi[INVESTIGATOR_887501]. IT  drug delivery was original ly developed to be a more efficient and efficacious method 
of delivering medication directly to the site of action, reducing the amount of drug needed. This idea suggests that targeted drug delivery (TDD) is more effective (e.g., smaller doses, equianalgesia, reduced side effects) than systemic drug administration of opi[INVESTIGATOR_75749]- malignant 
pain.  
Clinical evidence comparing systemic opi[INVESTIGATOR_887502]  a single larger randomized controlled trial (RCT) for malignant 
pain.  
3 Given the current opi[INVESTIGATOR_887503], it’s more important than 
ever for patients suffering from chronic pain to have access to proven alternatives. Clinical evidence 
specific to non -malignant pain and IT  morph ine sulfate is needed. This study is intended to augment 
existing medical evidence specific to the approved indication of treatment for chronic intractable pain of non-malignant origin. Current guidelines regarding patient  selection, trialing, implant, and  dosing for 
this therapy will be followed, allowing for selection and treatment of subjects in a manner similar to standard practice . TDD with  IT morphine may provide an opportunity to reduce drug dosing 
requirements, minimize opi[INVESTIGATOR_101315] -effects, and prov ide equivalent or improved analges ia. 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242228] to commonly 
accepted side effects related to opi[INVESTIGATOR_2441], including sleep disturbances, sedation, clouded thinking, 
constipation, and others.  
4.1.1  Preclinical Data  
IT m orphine use in the treatment of malignant pain date s back to the late 1970’s, with chronic infusion 
being used since the early 1980’s. Laboratory studies (in vitro and in vivo) supported this initial clinical use of IT morphine and the greater than 30 years of use as a therapy for chronic pain subjects preclude 
the need for additional preclinical data supporting this therapy. One noted exception, however, is the 
dose/concentration- dependent development of catheter tip inflammatory mass formation with chroni c 
IT delivery of morphine sulfate.
5–[ADDRESS_1242229] -market study using only commercially available products, a separate Investigator 
Brochure is not required. The Technical Manuals will be provided separately.  
4.1.2  Clinical Data  
The use of SynchroMed along with IT morphine for the treatment of chronic, intractable pain has been 
reported in published scientific literature; however, the level of quality (based on guidelines from the Center for Evidence- Based Medicine in Oxford)
a is limited.   
IT morphine has been used clinically since [ADDRESS_1242230] been published sup porting the use of the SynchroMed for the treatment of pain; 
three applicable to Prialt® (ziconotide) and one applicable to malignant pain (with morphine).3,9– [ADDRESS_1242231]  improved survival in subjects with refractory mal ignant pain. In this study, 
 
a OCEBM Levels of Evidence Working Group*. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence -Based 
Medicine. http://www.cebm.net/index.aspx?o=5653  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 16 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  IT drug use was limited to opi[INVESTIGATOR_2438] (morphine or hydromorphone, as this was an international study) 
during the first 4 weeks only and then opened to other medications as necessary to treat pain. Endpoint 
assessments were complete d at 4 weeks and showed improvement in pain visua l analog scale (VAS) 
scores for both Comprehensive Medical Management ( CMM ) and the Implantable Drug Delivery System 
(IDDS) with a non -statistically significant greater improvement in the TDD group. Improvem ent in 
toxicity scores was statistically significantly greater in the TDD group.  
Results of [ADDRESS_1242232] practices in three areas related to safe IT therapy for 
pain: safety and monitoring, patient and device management, and patient selection and trialing , the 
results of which were published in 2014 .20 They concluded that intrathecal drug delivery is a valuable 
alternative drug delivery system for many patients with severe chronic or end- of-life pain. They also 
noted that while device -related complications (mostly with catheters) and surgical -site infections can 
occur, the main therapy -related safety issues associated with IT  drug delivery arise primarily with 
inadequate pa tient monitoring (e.g., respi[INVESTIGATOR_2341]), inflammatory mass (e.g., high doses and 
concentrations of opi[INVESTIGATOR_2438]), wound healing, dosing errors (e.g., medication concentration and pump programming),  pump fills or refills (e.g., pocket fills), and interaction with concomitant systemic 
medications (e.g., opi[INVESTIGATOR_73773]). They stated that many of the reported adverse events and complications of IT  drug delivery can be prevented by [CONTACT_887559], implementation 
of best practices, an d experience. In adopting the therapy, patients must be apprised of its risks and 
benefits. Physicians and patients must partn er to achieve both safety and effectiveness . 
In 2000 a Polyanalgesic Consensus Conference (PACC) was convened for the first time t o review existing 
data specific to TDD and evaluate medical evidence gaps. The PACC convened most recently in [ADDRESS_1242233] practices and guidelines, improving safety and mitigating risks, and intrathecal trialing.
17–[ADDRESS_1242234] -market clinical study will be using the SynchroMed II infusion system with  
preservative- free morphine sulfa te, USP (PFMS) and preservative free 0.9% Sodium Chloride Injections, 
USP (for dilution) .  The study will be conducted at approximately [ADDRESS_1242235] their origin in the 
Declaration of Helsinki, all applicable regulatory requirements (21  Code of Federal Regulations  [CFR] §50 
Protection of Human Sub jects , 21CFR§ 54 Financial Disclosure by [CONTACT_6230], and 21CFR§ 56 
Institutional Review Boards [IRB], 21CFR§ 803 Medical Device Reporting ), and International Council for 
Harmo nizati on (ICH GCP E6) .  This study will be posted on ClinicalTrials.gov as part of Medtronic’s 
commitment to full disclosure for ongoing studies that meet the requirements for public posting.  
Documentation  for this study will be produced and maintained to ensure that a complete history of the 
study exists. Documents created for this study, including all versions of original documents, will be identifiable and appropriately stored to assure control and traceability of data related to this study . 
5. Objectives and/or Endpoints  
5.1 Objectives  
5.1.1  Primary Objective  
To characterize the proport ion of subjects with Clinical Success at the 6 -Month  Visit  based on changes in 
pain intensity using the Visual Analog Scale ( VAS) and changes in opi[INVESTIGATOR_2480] -related side effects using the 
Numerical Opi[INVESTIGATOR_887496] (NOSE) Assessment Tool.  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 18 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Clinical Success is defined as any of the following (refer to grid below with matching numbers) : 
1) Reduced opi[INVESTIGATOR_2480] -related side effects  with equal pain  
2) Reduced pain with equal opi[INVESTIGATOR_2480] -related side effects   
3) Reduced pain and reduced opi[INVESTIGATOR_2480] -related side effects   
Criteria for Clinical Success  
Change  
from Baseline  
to the 6 -Month  Visit   Opi[INVESTIGATOR_2480] -Related Side Effects  
Score (NOSE ) 
≥20% 
Increase  < ±20% 
Change  ≥20% 
Reduction  
Worse  Equal  Better  Pain Intensity (VAS)  ≥20% 
Increase  
Worse  
      
< ±20% 
Change  
Equal  
    1  
≥20% 
Reducti on 
Better  
   2  3 
5.1.2  Secondary Objectives  
1. To demonstrate pain intensity scores (VAS) at the [ADDRESS_1242236] scores (NOSE) from Baseline to the 6 -
Month Visit  
3. To characterize the proportion of subje cts who eliminate systemic opi[INVESTIGATOR_887497] 6 -Month 
Visit  
 
 
 
 
 
 

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 19 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template   
 
 
 
  
 
 
  
 
 
5.1.4  Safety Assessment  
To characterize all  systemic opi[INVESTIGATOR_208781] -related, device- related, IT drug -related,  and procedure -
related adverse events (AEs), all serious adverse events (SAEs) (regardless of relatedness) , and dev ice 
deficiencies  (DD) for all subjects from enrollment until the subject exits .  
6. Study Design  
This is a prospective,  multi -center, post market s tudy with commercially available products to e valuat e 
the pain control and opi[INVESTIGATOR_2480]- related side effects following  a route  of delivery change from  systemic 
opi[INVESTIGATOR_887504], intractable, non- malignant primary back 
pain with or without leg pain. The study will be conducted at approximately 15 study sites in the United 
State s. 
Patie nts that meet all inclusion criteria, do not meet any exclusion criteria, and provide written Informed 
Consent Form (ICF)/ Health Insurance Portability and Accountability Act  (HIPAA ) Authorization Form will 
be enrolled in the study. Medtronic produc ts used in this study will be used within the specifications of 
product labeling . The pharmacological agent used in the study is limited to  PFMS  and preservative free 
0.9% Sodium Chloride Injections, USP (for dilution).  
Ninety -three subjects have been enro lled into the study with the intent to achieve  approximately  [ADDRESS_1242237] been considered and minimized by 
[CONTACT_54415]. Methods incorporated in the study design to minimize potential bias include (but 
are not limited to) the following : 
• Subjects  will be screened to confirm eligibility for enrollment with defined inclusion/exclusion 
criteria  
• Subject demographics will be collected to assess possible characteristics that may influence 
endpoints  
• To ensure widespread distribution and data among  centers, the maximum number of subjects 
that may be enrolled at a single site is 15, with Medtronic pre -approval required for additional 
enrollments . Additionally, centers will each be encouraged to enroll at least 5 subjects  
• A statistical analysis pla n will be developed prior to analyzing data which will document pre -
specified analysis and analysis methods  
• All study site personnel  and Medtronic personnel will be trained on their respective aspects of 
the study using standardized training materials  
• All stu dy site personnel will be trained on and required to follow the Clinical Investigation Plan  
(CIP) 
• A Clinical Events Committee (CEC) will be utilized to adjudicate the relatedness and seriousness 
classifications of all reportable AEs and deaths  
   
 
  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 21 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template   
Figure 1: Embrace TDD Study Visit Flowchart  
 

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242238] signs the study informed consent /HIPAA form . 
Enrolled subjects will be required to attend a minimum of [ADDRESS_1242239] is defined as the conclusion  of the 6-Month Visit (Study Exit) . Each s ubject ’s participation  in the 
study  is expected to last approximately [ADDRESS_1242240] approximately 3  
years . Study completion is defined as the approval  of the Final Study Report  and closure of all study 
sites.   
6.2 Rationale  
Information from available literature (Section 4.1 ) supports the need for clinical  studies to assess IT 
morphine as an alternative route of delivery an d its impact  on e fficacy and safety outcomes. Many 
chronic pain patients  may not be achieving adequate pain management with systemic agents, are at 
higher risk for dose -limiting side effects or can become tolerant to opi[INVESTIGATOR_487640]. Additionally, by 
[CONTACT_887560] o f delivery, there is potential to eliminate the need for adjunctive chronic systemic 
opi[INVESTIGATOR_2438], which may lead to a reduction of opi[INVESTIGATOR_2480]- related systemic side effects.  
Studies of systemic opi[INVESTIGATOR_887505] a fun ction of increase d daily dose. 
Dunn et al. reported that adults who started use of opi[INVESTIGATOR_512185] a pain condition and were 
receiving 100 mg per day or more of an average prescribed daily opi[INVESTIGATOR_887506] 8.9 -fold increase in 
overdose risk compare d with subjects r eceiving 1 to 20 mg/day of these medications. Furthermore, 
subjects receiving 50 to 99 mg/day had a 3.[ADDRESS_1242241] level. Smith et al3 reported the use of a combination 
endpoint with malignant pain subjects, with clinical success defined as a ≥20% reduction in VAS, or equal 
pain scores with ≥ 20% reduction in opi[INVESTIGATOR_2480] -related side effects .  
This study is designed to establish medical evi dence that intrathecal morphine is an effective alternative 
for the management of chronic intractable pain and implementing an opi[INVESTIGATOR_887507].   
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242242] labeling .  
The pharmacological agent used in the study is limited to PFMS and preservati ve free 0.9% Sodium 
Chloride Injections, USP (for dilution).   
Table 1: Study Products   Medtronic Product  Model  Implantable 
Components  
 
 
 
 
 
 Pump  8637 -20 SynchroMed ™ II Pump  
8637 -40 SynchroMed ™ II Pump  
Catheters  8780 Ascenda™ Int rathecal Catheter Kit  
8781 Ascenda™ Intrathecal Catheter Kit  
8782 Ascenda™ Intrathecal Catheter Spi[INVESTIGATOR_887508]  
8784 Ascenda™ Intrathecal Catheter Pump Segment Revision Kit
  Catheter Accessory Kits  8785 Catheter Accessory Kit  
8786 Needle Cathe ter, Short  
8787 Needle Catheter, Long   
8591- 38 Catheter Passer  
8591 -60 Catheter Passer   Refill Kit and Catheter 
Access Port Kit  8540 Catheter Access Port Kit  
8551 Refill Kit  
8555 Refill Kit    Clinician Devices  CT900 Clinician Programmer (tablet)  
A810 S ynchroMed II Clinician Programmer Application  
A901 Communicator Manager  Application  
A902 Patient Data Service App lication  
8880T2 Communicator   Patient 
Devices/Accessories  TH90T01 Personal Therapy Manager (myPTM™)  
TM90 Communicator  
HH90  Handset with A820 myPTM Application software  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 24 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  SynchroMed II infusion system Manuals are provided with the products and are also available 
electronically at http://manuals.medtronic.com/manuals/main/region . 
7.2 Dosage Form and Route of Admini stration  
Sites will utilize  PFMS per the investigator’s standard of care and in accordance with the IT PFMS dosing 
goals and IT PFMS dose adjustment parameters outlined in Section 10.13 . 
Preservativ e-free (0.9%) Sodium Chloride Injection for IT administration: may be used to dilute PFMS to 
the desired concentration or to fill the p ump reservoir prior to introduction of PFMS or if PFMS is 
removed and no other drug  is placed in the pump.    
7.[ADDRESS_1242243] labeling and their institution’s policies and procedures.  
The pharmacological agent used in this study will be PFMS. Each study site will order drug through their standard ordering processes and should follow their own accountability and storage processes, in accordance with the product labeling and their institution’s policies and procedures, since these are 
controlled substances.  No additional product accountability logs will be required for tracking these 
commercially available products in this study. All Medtronic device product manuals  can be found 
electronically at http://manuals.medtronic.com/manuals/main/region
. 
7.5 Intended Population  
The SynchroMed II infusion system is utilized in this study to deliver PFMS intrathecally in  the treatment 
of patients with chronic, intractable, non- malignant, primary back pain with or without leg pain who are 
experiencing inadequate pain relief and/or intolerable side effects with their  systemic opi[INVESTIGATOR_2538] . 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242244] 
exposed to the IDDS (during the device implant visit)  until either the IDDS is explanted or the subject 
discontinues from the study .  
7.[ADDRESS_1242245] proper delegation by [CONTACT_079] (PI) on the 
Delegation of Authority Log maintained at the site.  
7.[ADDRESS_1242246] keepi[INVESTIGATOR_887509], per 
applicable labeling and per their institutions’ policies and  procedures.  
7.[ADDRESS_1242247] be disposed of as required by [CONTACT_887561]’s institutional 
policies and procedures.  
Returned P roduct A nalysis  
Devices that are returned to Medtronic, Inc. are analyzed via a  Returned Prod uct Analysis (RPA) system 
following  specific protocols to identify root cause for failure or deficiency. When programming data are  
available on the IDDS , an expected longevity can be determined, and battery depletion (where 
applicable) can be identified as normal or prematu re. Upon PI [CONTACT_32236], a summary report of Medtronic’s 
findings will be provided to the PI [INVESTIGATOR_887510].  
7.[ADDRESS_1242248] labeling and the institutions’ standard procedure s.  
8. Study Site Requirements  
All investigator and site selection activities were complete prior to implementation of CIP V3 .0. 
8.1 Investigator/Investigation Site Selection  
All investigators managing the subject’s chronic pain must be qualified practitioners and experienced in 
the diagnosis and treatment of subjects with chronic pain.  All PIs or appropriately delegated Sub-
Investigator s must be experienced and/or trained in the implant and management of the Medtronic 
SynchroMed II infusion system . 
The role of  the principal investigator [INVESTIGATOR_54365] -to-day conduct of the clinical 
investigation as well as ensure data integrity and the rights, safety and well -being of the subjects 
involved in the clinica l investigation.  
The principal inves tigator shall:  
• Be qualified by [CONTACT_8640], training, and experience to assume responsibility for the proper 
conduct of the clinical investigation  
• Be experienced in the field of application and training in the use of  the Medtronic 
SynchroMed II infusion syst em 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 27 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  • Disclose potential conflicts of interest, including financial, that interfere with the conduct of 
the clinical investigation or interpretation of results  
• Be able to demonstrate that the proposed investigational study site:  
 Has the required number of eli gible subjects needed within the recruitment period  
 Has one or more qualified investigators, a qualified investigational study site team and adequate facilities for the foreseen duration of the clinical investigation  
Study site personnel training will be completed and documented prior to participation in this study.  
8.2 Study Site Activation  
During the activation process (prior to subject enrollment), Medtronic will train study site personnel according to their delegated tasks and in accordance with the study  training plan . If new members join 
the study site team, they will receive training on the applicable study requirements relevant to their role before contributing to the study.  
Prior to p erforming study related activities, all regulatory requirements shal l be fulfilled, including, but 
not limited to the following:  
• IRB approval of CIP and site -specific ICF   
• Fully executed C linical Trial Agreement   
• Financial disclosure  
• Curriculum Vit ae of investigators and key members of the investigation study site te am   
• Documentation of delegated tasks  
• Documentation of study training  
• Additional requirements imposed by  [CONTACT_837826], if appropriate.  
Medtronic will provide each study site with documentation of study site/investigator readiness; this letter must be received prior to performing study related activities.  
9. Selection of Subjects  
9.[ADDRESS_1242249] Enrollment  
93 subjects with chronic, intractable, non- malignant primary back pain with or without leg pain that met 
eligibility criteria and provided written informed consent/HIPAA were enrolled in this study.  Subjects 
were enrolled at [ADDRESS_1242250] has/is:  
1. Willing and able to provide a signed and dated (Medtronic and Institutional Review Board ( IRB) 
approved) Informed Consent Form (ICF) and Health Insurance Portability and Accountability Act  
(HIPAA ) Authorization Form prior to any study procedures being performed  
2. A candidate pe r labeling for the IDDS  
3. A diagnosis of chronic , intractable , non -malignant primary back  pain with or without leg pain, 
treatable with  the IDDS   
4. Current daily systemic opi[INVESTIGATOR_887511] >0 and ≤  120 Morphine Milligram Equivalents ( MME ) 
5. A Visual Analogue Scale ( VAS) of ≥5 0 mm  for pain intensity at the Baseline Visit and/ or a Numerical 
Opi[INVESTIGATOR_887496] (NOSE) Assessment Tool ≥[ADDRESS_1242251] -menopausal or surgically sterile ; 
or be utilizing a medically acceptable form of birth control (i.e. a hormonal contraceptive, intra -
uterine device, diaphragm with spermicide, or condom with spermicide) for the duration of the 
study 
9.[ADDRESS_1242252] has/is:  
1. Previously trialed or implanted with an IDDS  
2. Concomitant stimulation device implanted for the treatment of pain  
3. Any ongoing health condition that would be expected to interfere with pain and/or quality of life 
ratings ( i.e. active malignancy, other painful conditions not treata ble with IT therapy, etc.)  
4. Psychological or other health conditions, financial and/or legal concerns that would interfere with the su bject’s ability to fulfill the requirements of the protocol as per the investigator’s discretion  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 29 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  5. Substance U se D isorder (SUD) within the last 2  years or current Medication Assisted Treatment 
(MAT) for substance use disorder  
6. Currently using cannabinoids  or illicit drugs 
7. History of allergy or significant adverse reaction to morphine per investigator discretion  
8. Currently participating or plans to participate in another investigational study unless written 
approval is provided by [CONTACT_887562]  
10. Study Pro cedures  
10.1 Summary of Visits  
Study procedures and data collection requirements for the study are provided in detail below for each 
visit and summarized in Table 3 : Schedule of Events within Section 10.11 . Refer to Section 6 , Figure 1 : 
Embrace TDD Study Visit Flowchart for a diagram of the required study visits.  
A summary of the required visits are as follows :  
• Baseline  Visit  
• Intrathecal Trial Visit  
• Implant  Visit  
• Post -Op Visit  
• 1-Month Visit  
• 3-Month Visit  
• 6-Mon th (Study Exit) Visit  
 
Table 2 : Visit Windows provides details regarding the study visit windows for all required study visits.  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 30 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Table 2: Visit Windows  
 Study Visits  Visit Windows  
Baselin e Visit  Date of Enrollment  
(Date ICF/HIPAA signed and dated)  
Intrathecal Trial Visit  After Baseline and p rior to Implant  
IT Therapy Initiation  
(Day 0)  
Implant to Post- Op 
Visit  Implant Visit   ≤ [ADDRESS_1242253] -Op Visit  14 ± 4 d ays after the Implant Visit  
 1-Month Visit  30 days  ± 5 days after Day 0  
3-Month Visit  90 days ± 10 days  after Day 0  
6-Month Visit  (Study Exit)  180 days ± 10 days  after Day 0  
 
10.2 Baseline Visit  
Subjects are considered enrolled at the time the study -spec ific informed consent /HIPAA  form is signed.  
At the Baseline  Visit, the Medtronic and site Institutional Review Board (IRB) approved informed 
consent/HIPAA form will be reviewed with the potential s ubject. If the subject agrees to participate, 
they will be  consented and assessed for eligibility to the study -specific inclusion  and exclusion criteria. 
Each subject must meet  all the inclusion criteria and none of the exclusion criteria to be eligible to 
parti cipate in this study.  No study -related procedures o r testing will be conducted prior to completing 
the consenting process of a subject.  
Subjects will be asked to complete the VAS for pain intensity and the NOSE assessment tool. Site 
personnel will confirm  the subject’s VAS score ≥ [ADDRESS_1242254]’s NOSE score ≥ 40 to be  eligibl e to 
continue in the study.   Female subjects of child -bearing potential (not post -menopausal or surgically 
sterile ) must be administered a urine pregnancy test to confirm they a re not pregnant at this visit.  A 
subject who has a positive urine pregnancy test  will be exited from the study according to S ection 10.[ADDRESS_1242255] confirm the drug testing results are negative for cannabinoids and illicit 
drugs for all subjects. If subjects  meet all the eligibility  criteria , their chronic back (and leg, if applicable) 
pain history and surgical history will be  collected and the study investigator will discuss the process for 
weaning off systemic opi[INVESTIGATOR_887512].  
Systemic Opi[INVESTIGATOR_887513]18026  Version  3.[ADDRESS_1242256] off their systemic opi[INVESTIGATOR_887514] (i.e., enrolment date). The method of the opi[INVESTIGATOR_887515]’s discretion, 
but must be completed within the following constraints:  
• Total duration (Baseline to Implant ≤ 5 months)  
• Systemic opi[INVESTIGATOR_199692] ≤ 60 MME be fore IT trial  
• Minimum opi[INVESTIGATOR_887516] [ADDRESS_1242257] will be exited a ccording to Section 10.10 .   
Data Collection Requirements for the Baseline Visit:  
• ICF/HIPAA  
• Inclusion/exclusion criteria  
• VAS 
• NOSE 
• Demographics  
• Back (and leg , if present)  pain history/surgical history  
• Adjunctive pain management therapi[INVESTIGATOR_887517]  
• Urine pregnancy test results, if applicable  
• Drug testing for systemic opi[INVESTIGATOR_2438] , cannabinoids,  and illicit  drug use   
 
 
• Pai
n medications  
• AEs  
10.[ADDRESS_1242258]’s systemic opi[INVESTIGATOR_887518] ≤ [ADDRESS_1242259] with the IT drug trial. Females of child -bearing potential (not post -menopausal or surgically 
sterile ) must be administered a urine pregnancy test at this visit to confirm they are not pregnant. In 
addition, site personnel must confirm each subject’s drug testing results for systemic opi[INVESTIGATOR_887519]. If it is determined the subject no longer meets eligibility criteria, o r they choose to withdraw early, the subject will be exited from the study  
according to S ection 10.10 .  
The IT trial will be conducted according to the investigator’s standard of care procedures. A successful IT 
trial will be determined by [CONTACT_887563].  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242260] will be considered a screen 
failure and will be exited from the study according to Section 10.10 . 
Data C ollection R equirements for the IT Trial Visit : 
• Inclusion/exclusion criteria   
• VAS 
• NOSE  
• Adjunctive pain management therapi[INVESTIGATOR_887517]  
• Urine pregnancy test results, if applicable  
• Drug testing results for systemic opi[INVESTIGATOR_2438], cannabinoids , and illicit drugs  
• Date systemic opi[INVESTIGATOR_887520], if prior to trial  
• IT trial method, drug name, lot number/identifier, dose(s) and concentration(s)  
• Pain medications  
• AEs 
10.[ADDRESS_1242261] occur ≤150 days after  the Baseline Visit. Females of child -bearing potential (not 
post -menopausal or surgically sterile ) must be administered a urine pregnancy test within 2 weeks prior 
to the implant  visit to confirm they are not pr egnant.  
Only investigators who are trained and experience d in implanting the SynchroMed II infusion system 
and trained by [CONTACT_887564]. The IDDS 
will be implanted per the investigator’s stand ard procedures. Investigators performing the  implant 
should obtain a final intra -operative fluoroscop y or anteroposterior and lateral x -ray to confirm catheter  
placement. Initial device interrogations and data uploads must be completed at implant and final  
interrogation prior to discharge.  
The inves tigator may determine whether to initiate IT therapy at the Implant Visit or after the Implant 
Visit and up to the date of the Post -Op Visit. If IT therapy is initiated at the Implant, refer to Section 10.[ADDRESS_1242262]’s medical records and on the applicable Electronic Case Report 
Form(s) (eCRF). 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242263].  
Data C ollection R equirements for the Implant Visit: 
• Date systemic opi[INVESTIGATOR_887520], if prior to the implant  
• Adjunctive pain management therapi[INVESTIGATOR_887517]  
• Confirm urine pregnancy test completed within 2 weeks prior to implant, if applicable  
• Final AP and lateral fluoroscopic/x -ray images to confirm catheter tip location  
• Device information, (including Model # and Serial/Lot #) will be collected for each of the 
following:  
o Pump  
o Catheter  
o myPTM (if distributed)  
• Initial and final device interrogation reports (at implant and prior to discharge)  
• Pain medication s 
• AEs/DDs  
10.[ADDRESS_1242264] occur 14 days ±[ADDRESS_1242265]’s implant wound to confirm it has healed appropriately and document any relevant observations 
in the medical records (source records). The following activities must also be completed during the visit: 
initial and final device interrogations and data uploads, if device was interrogated, date systemic opio ids 
were stopped (if after implant), pain medications, AEs and DDs must be documented in the subject’s 
source.  
Use of myPTM for each subject will be at the discretion of the investigator and subject.    
If IT therapy is initiated at this visit, refer to Se ction 10.[ADDRESS_1242266] -Op Visit : 
• Date systemic opio ids were stopped, if after implant  
• Initial and final devic e interrogation reports  
• Pain medications  
• AEs/DDs  
10.[ADDRESS_1242267] -Op Visit, females of child -bearing  potential ( not post -menopausal or 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 34 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  surgically sterile ) must be administered a urine pregnancy test at this visit to confirm they are not 
pregnant, before initiating IT PFMS. In addition, site personnel must confirm the drug testing results are 
negative for  systemic opi[INVESTIGATOR_2438], cannabinoids, and illicit d rugs.  
Only  PFMS and 0.9% solution of preservative -free sodium  chloride injection (USP) for dilution  
will be allowed in the pump from the IT Therapy Initiation Visit through the [ADDRESS_1242268] on the use of the myPTM during this visit.  
Data C ollection R equirements for IT Therapy Initiation : 
• VAS 
• NOSE  
• Date systemic opi[INVESTIGATOR_887520], if applicable  
• Adjunctive pain management therapi[INVESTIGATOR_887517]  
• Urine pregnancy test, if applicable  
• Drug test ing results  for systemic opi[INVESTIGATOR_2438], cannabinoids,  and illicit drugs  
• Drug information including:  
o Drug name  
o Lot #/identifier  
o Dose  
o Concentr ation  
• Initial and final device interrogation reports  
• Pain medications  
• AEs/ DDs 
10.7 1-, 3-, and 6-Month Visits  
Visits will be required at 1, 3, and 6 months after IT Therapy Initiation (Day 0) . Visit windows are as 
follow for these visits:  
1-Month Visit  30 days  ± 5 days after Day 0  
3-Month Visit  90 days ± 10 days  after Day 0  
6-Month Visit  180 days ± [ADDRESS_1242269] be completed.  
Data C ollection  Requirements for the 1-, 3- , and 6 -Month Visits : 
• VAS 
• NOSE  
• Urine pregnancy test, if applicable  
• Drug test ing results  for systemic opi[INVESTIGATOR_2438], cannabinoids , and illicit drug s 
• Actual r esidual and fill volume (if pump refill occurs during  visit)  
• Drug information (if pump refill occurs during visit) including:  
o Drug name  
o Lot #/identifier  
o Dose  
o Concentration  
• Initial and final device interrogation reports  
• Pain medications  
• AEs/DDs  
 
   
   
   
   
 
  
10.8 Unscheduled Visits  
Unscheduled visits may occur during the study for reasons including dose adjustments, programming 
adjustments, pump refills, medication changes (if subject is unable to be successfully managed on morphine monotherapy), AEs , and DDs.  
Subjects will be asked to complete the VAS for pain intensity and the NOSE assessment tool prior to site personnel performing other v isit activities.  
PFMS dose adjustments may be made during unscheduled visits if necessary,  to manage subject pain or 
opi[INVESTIGATOR_2480] -related side effects. PFMS dosing will be managed according to the IT PFMS administration and 
dosing parameters outlined in Section 10.13  and pump refills will be handled as required in Section 
10.12 . 

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 36 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Data C ollection R equirements for Unscheduled Visits:  
• VAS 
• NOSE  
• Reason for the unscheduled visit  
• Actual r esidual and fill volume (if pump refill occurs during  visit)   
• Drug information (if pump refill occurs during  visit ) including:  
o Drug name  
o Lot #/identifier  
o Dose  
o Concentration  
• Initial and final device interrogation reports  
• Pain medications  
• AEs/DDs  
10.[ADDRESS_1242270] be reported in the event the catheter and/or pump  require surgical 
modification. Programming of a new PFMS dose  or refilling the pump are  not considered system 
modification s. In the event of a system modificati on, the follow -up schedule for the subject will remain 
unchanged.  
Data C ollection R equirements for System Modifications : 
• VAS 
• NOSE  
• Reason for system modification and all affected components  
• Initial and final device interrogation reports for the existing pump  
• Actual residual volume of existing pump   
• Drug information (if pump refill occurs during  visit ) including:  
o Drug name  
o Lot #/identifier  
o Dose  
o Concentration  
• Initial and final device interrogation reports for new pump, if applicable  
• Pain medications  
• AEs/DD s 
10.[ADDRESS_1242271] has completed the required study visits through the 
6-Month Visit  (refer to required procedures described in Section 10.7 ), at which time the subjec t will 
end their participation in the study and site personnel will then complete required eCRFs.  If a subject 
has already complete d their [ADDRESS_1242272] withdrawal or 
discontinuation procedures.  
10.11 Schedule of Events  
Table 3: Schedule of Events  
Study Procedures, 
Tasks, and Data 
Collection (row) by [CONTACT_4838] 
(colum n) 
Baseline Visit  (Enrollment)  
Intrathecal  Trial Visit  
Implant Visit  
Post -Op Visit  
IT Therapy Initiation  
1-Month Visit  
3-Month Visit  
6-Month Visit  (Study Exit)  
Unscheduled Visits  
Informed Consent Process  √         
Demographics  √         
Inclusion/Exclusion Criteria  √ √        
Urine Pregnancy Test  √ √ √1  √ √ √ √  
Drug Test √ √   √ √ √ √  
Adjunctive pain 
management therapi[INVESTIGATOR_014]  √ √ √  √     
Back and Leg Pain/Surgical 
History  √         
VAS √ √   √ √ √ √ √ 
NOSE  Assessment  √ √   √ √ √ √ √ 
IT PFMS  Dose      √ √ √ √ √ 
          
          
          
 
          
 
          
 
          
Fluoroscopy/x -ray    √       
Device information (model, 
serial/lot #)   √       
Drug information (name, 
lot #/identifier, dose & 
concentration)   √   
√ √ √ √ √ 
Initial and final device 
interrogation reports    √ √ √ √ √ √ √ 
Collect AE s/DDs √2 √ √2 √ √ √ √ √ √ 
Pain Medications  √ √ √ √ √ √ √ √ √ 
1Confirm  pregnancy test completed within 2 weeks prior to implant visit 
2Device Deficiencies will be collected and reported from the Implant Visit through the 6-Month  Visit/Study Exit  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 38 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  10.12  Pump Refills  
Pump refills will be performed by  [CONTACT_887565], filling , and dose modification of SynchroMed II  infusion system.  
• Pump refill procedures may occur at sched uled or unscheduled visits.  
• Careful monitoring of the refill schedule must be done to prevent reservoir depletion and 
potential adverse events.  
• Any drug remaining in the pump reservoir at the time of refill should be removed and discarded, and the pump reservoir should be refilled (document the actual residual volume, the refill volume, the drug concentration, and dose in the subject’s medical record).  
 
Refer to Section  10.[ADDRESS_1242273] be within the following evidence -based 
consensus guidelines and remain in line with study dosing goals.  
IT PFMS Dosing Goal:  
To mai ntain  or improve pain control and/or opi[INVESTIGATOR_2480]- related side effects (compared to Baseline) with 
utilization of the lowest reasonable daily dose of IT PFMS following discontinuation of all systemic opi[INVESTIGATOR_887521] i nfusion system.  
PFMS, at a concentration not exceeding 25 mg/mL and 0.9% solution of preservative -free sodium 
chloride injection (USP) for dilution, will be the only drug allowed in the pump from the IT Therapy Initiation Visit through the duration of the study, i f possible.  
IT PFMS Dose Initiation Parameters: 
IT PFMS may be initiated at Implant, the Post- Op Visit, or any time in between  per investigator standard 
practice and patie nt-specific therapy needs. Standard guidelines for intrathecal PFMS dosing initiation 
include:  
• A starting PFMS dose of 0.1 to 0.5 mg/day, or half the effective trial dose, with lower initial 
PFMS doses considered, as needed, dependent upon the duration of opi[INVESTIGATOR_887500]. 
Determination of IT PFMS dosing based on previous systemic opi[INVESTIGATOR_887522].  
• A starting concentration to achieve an estimated pump refill interval of 120 days, but not to 
exceed 180 days  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 39 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  • Patients may initiate myPTM use at any point during the study.   
 
IT PFMS Dos e Adjustment Parameters : 
Study investigators or appropriately trained and delegated designees experienced with the use, filling , 
and dose modification of the SynchroMed II infusion system will be responsible for administering and 
adjusting PFMS doses in this study. The investigator is r esponsible for overseeing and managing dosing 
in accordance with the IT dosing goal and the following instructions:  
• IT PFMS dose increases or decreases can be made any time throughout th e duration of study.  
• IT PFMS Dose adjustments (increase or decrease) c ompleted outside of a protocol -required visit 
will be considered an Unscheduled Visit. Initial PFMS dose increases following implant may be 
higher depending on the starting IT PFMS dose.  Subsequent increases should only be made in 
response to inadequate pa in control with increases as low as possible, but not exceeding 25%, 
to achieve adequate pain control  
10.14  Prior and Concomitant Medications   
Only those s ubjects who are on  a daily dose of >  0 and ≤120 MME of systemic opi[INVESTIGATOR_2438] (at the time of 
enrollment) will be eligible for participation in the study.  Medications prescribed for the treatment of  
pain will be collected during  the study and documented in the subject’s medical records and on the  
applicable eCRF(s) . Non- opi[INVESTIGATOR_887523] -operative pain at the  discretion of the investigator, although it is 
recommended that these medication s remain as stable as possib le or be decreased as appropriate. 
Increases in these medications are discouraged. Systemic opi[INVESTIGATOR_2480] s may be taken to manage  post -
operative pain , if IT therapy is not being initiated at the Implant Visit, as long as the subject has a 
minimum of a 7- day opi[INVESTIGATOR_2495] d holiday prior to the date of IT Therapy Initiation.  
10.[ADDRESS_1242274] population. Prior to enrolling subje cts, each investigational 
site’s IRB will be require d to approve the CIP, ICF and HIPAA/data protection authorization or other 
privacy language (where required by [CONTACT_2371]), and any other written study information to be provided to 
the subjects  (e.g. CA Bill of  Rights if applicable, subject assessments) . The doc ument(s) must be 
controlled (i.e. version number and date) to ensure it is clear which version(s) were approved by [CONTACT_1201]. 
Any adaptation of the informed conse nt form must be reviewed and approved by  [CONTACT_887566] s. The ICF will be provided separately . 
Patient informed consent is defined as legally effective, documented confirmation of a subject’s 
voluntary agreement to participate in a clinical study after inform ation has been given to the subject on 
all aspects o f the clinical study that are relevant to the subject’s decision to participate. The informed 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242275]’s decision to participate throughout 
the clinical investigation including, but not limited to, the following: purpose and nature of the study , 
study procedures, expected study duration, available alternative therapi[INVESTIGATOR_014], and the benefits a nd risks 
involved with study participation and the potential treatment.  
The investigator shall seek such consent only under circumstances that provide the prosp ective subject 
sufficient opportunity to consider whether to participate , and that minimize the possibility of coercion 
or undue influence. No informed consent, whether oral or written, may include any exculpatory 
language through which the subject is made  to waive or appear to waive any of the subject’s legal rights, 
or releases or appears to releas e the investigator, the sponsor, the institution, or its agents from liability 
for negligence.  
Subjects are considered enrolled at the time the study -specific ICF  is signed. Informed consent must be 
obtained from the subject prior to initiation of any study -specific procedures. Subjects must be able to 
personally sign and date the consent form to participate in this study. Signing and dating of the ICF or HIPAA authorization form by a legally authorized representative will not be permitted for this study. 
Subjects will be required to sign and date a HIPAA authorization form before participating sites can 
collect, use and submit subject information to the study sp onsor. The Consent Form and Authorization 
to Use and Disclose Personal Health Information/ Resea rch Authorization/other privacy language , as 
required by [CONTACT_2371] , must be given to the subject in a language he/she is able to read and understand.  
As the ICF is e xpected to be signed on the same day, but prior to any Baseline Visit study -related 
procedures, it will be documented in the subject’s case history and consent documentation that consent 
was obtained prior to participation in any study related procedures.   
The signed and dated ICF must be filed in the hospi[INVESTIGATOR_307]/clinical chart and/or  with the subject’ s study 
documents. A copy of the informed conse nt form and signed Authorization to Use and Disclose Personal 
Health Information/Research Authorization/other pri vacy language , as required by [CONTACT_2371] , must also  be 
provided to the subject.  The signed and dated i nformed conse nt form and Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy language , as required by [CONTACT_2371] , as wel l as 
documentation of the individual informed consent process  must be available for monitoring a nd 
auditing.  Any changes to a previously approved informed conse nt form throughout the course of the study must 
be submitted to and approved by  [CONTACT_13753] t he IRB reviewing the application before being used to 
Embrace TDD Clinical Investigation Plan  Form  
MDT18026  Version  3.[ADDRESS_1242276]. The document(s) must be controlled (i.e. versioned and dated) to 
ensure it is clear which version(s) are approved  and current  by [CONTACT_1201].  
The investigator must notify the subject of any significant new findings about the study that become available during the study which are pertinent to the safety and well -being of the subject, as this could 
impact a subject’s willingness to continue participat ion in the study.  
10.16  Medication Compliance  
Subjects  will be required to wean off all systemic opi[INVESTIGATOR_887524] y Initiation.  Drug testing 
(urine, blood, or oral fluid) will be administered at the Baseline Visit to confirm the subject is not currently taking any cannabinoids or illicit drugs. Patients will be weaned off all systemic opi[INVESTIGATOR_887525] a strict op ioid-free holi day period of at least 7 days prior to initiating IT PFMS therapy . 
Confirmation that the patient has successfully ceased taking systemic opi[INVESTIGATOR_887526] . 
Drug testing will be completed at each scheduled follow -up visit after the initiation of IT morphine 
monotherapy through the 6- Month/Study Exit Visit  to confirm they are compliant and not taking any 
systemic opi[INVESTIGATOR_2438], cannabinoids, or illicit drugs.  
10.17 Assessment of Efficacy  
10.17.1  Visual Analog Scale (VAS)  
Pain will be assessed using VAS. The VAS is a 100 mm line, with “No pain” on the left side of the line and 
“Worst pain imaginable” on the right  side of the line . Subjects will be a sked to mark a line perpendicular 
to the VAS line that best describes their average pain in the last [ADDRESS_1242277] Assessment Tool (NOSE)  
The Numerical Opi[INVESTIGATOR_887496] (NOSE) Assessment Tool is a tool to evaluate 10 opi[INVESTIGATOR_2480] -related side 
effects using a 11 -point numeric scale.19 Subjects are as ked to evaluate each of the 10 opi[INVESTIGATOR_2480]- related 
side effects on a scale of 0 -10 with 0 being not present and 10 being as bad as you can imagine. A total 
sum score can range from 0 -100. The opi[INVESTIGATOR_887527]: 1) Nausea, vomiting , and/or lack of 
appetite; 2) Fatigue, sleepi[INVESTIGATOR_008], trouble concentrating, hallucinations, and/or drowsiness/somnolence; 
3) Constipation; 4) Itching; 5) Decreased sexual desire/function and/or diminished libido; 6) Dry mouth;
7) Abdominal pain or discomfort/crampi[INVESTIGATOR_887528]; 8) Sweating; 9) Headache and/or dizziness; 10)Urinary retention. The score from each side effect as well as the total sum score from all side effectsmay be reported.
Embrace TDD Clinical Investigation Plan  Form  
MDT18026  Version  3.0 Page 42 of 74 
   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 43 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template    
  
  
  
  
 
  
  
  
  
  
  
 
 
  
 
 
 
  
 
 
  
  
  
  
  
  
  
 
 
 
 
 
10.18  Assessment of Safety  
Subjects will  be assessed from enrollment through the end of the study for AEs related to the following:  
• Systemic opi[INVESTIGATOR_2495] d weaning  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 44 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  • Device  
• IT drug  
• Procedure  
 
In addition, all SAEs (regardless of relatedness) and  device deficiencies reported during the study will be 
collected. All subject deaths (regardless of relatedness)  must be reported to Medtronic according to 
Section 12 .6.  
10.19  Recording Data  
This study will be utilizing  a Remote D ata C apture (RDC) system  to collec t study required Case Report 
Form (CRF) information.   Electronic CRFs (eCRFs) will be provided by [CONTACT_456]; require d data will be 
recorded  from source documents and entered into the study database via the e CRFs by [CONTACT_887567], in accordance with applicable regulations.   Source 
documentation for VAS  and other subject assessments will be ca ptured in a paper format and 
completed confidentially by [CONTACT_887568] .  Source documentation for NOSE will be captured in a 
paper format and completed by [CONTACT_978] [INVESTIGATOR_18970]- investigator.   Data from the paper assessments 
will be entered into the database by [CONTACT_887569] e personnel  after ensuring the completeness and 
accuracy of the data .   
The PI [INVESTIGATOR_887529]. The PI [INVESTIGATOR_779435] s ub-investigator  (physician only)  is required to approve  all data on e CRFs via 
electronic signature . 
SynchroMed II programming data (interrogation and pump programming parameters) captured and 
recorded by [CONTACT_887570] A810 application will be uploaded to a secure databas e. 
The Clinical Data Upload application is a tool available for installation on and use with the Clinician 
Programmer that allows clinicians to electronically transfer and save session data files to a secure 
Medtronic database.  
10.20  Deviation Handling  
A deviat ion is defined as an instance(s) of failure to follow, intentionally or unintentionally, the 
requirements of the clinical investigational plan.  The investigator is not allowed to deviate from the CIP, 
except under emergency circumstances to protect the rig hts, safety and well- being of human subjects.   
All study deviations must be reported on the eCRFs regardless of whether medically justifiable, pre -
approved by [CONTACT_13735], an inadvertent occurrence, or taken to protect the subject in an emergency.  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242278] comply with IRB  policies, local laws, and/or regulatory 
agency requirements.  
If a deviation involves a failure to obtain a subject’s consent or the deviation is made to protect the life 
or physical well -being of a subject in an emergency, the deviation must be reported to the IRB  as well as 
Medtronic within five (5) working days.   
In situations where the investigator anticip ates, contemplates, or makes a conscious decision to deviate  
from the CIP, the investigator must provide Medtronic with his/her request to deviate from the CIP. 
Medtronic will respond to all requests in writing. If approved, and the deviation affects a subject’s  rights, 
safety and well -being, or the scientific integrity of the study, prior approval from IRB is also required.  
Prior written approval from Medtronic  is not required when a deviation is necessary to protect the 
rights , safety  or well -being of a subjec t in an emergency or in unforeseen situations beyond the 
investigator’s control (e.g. subject failure to attend scheduled follow -up visits, inadvertent loss of data 
due to computer malfunction, inability to perform required procedures due to subject illness).  
Medtronic is responsible for analyzing deviations, assessing their significance, and identifying any additional corrective and/or preventive actions (e.g. amend the CIP , conduct additional training, or 
terminate the investigation). Repetitive or seriou s investigator compliance issues may result in initiation 
of a corrective action plan with the investigator and site, and in some cases, necessitate suspending 
enrollment until the problem is resolved or ultimately terminating the investigator's participat ion in the 
study.  
Examples of study deviations include but are not limited to the following:  
• Failure to obtain informed consent or HIPAA authorization prior to study enrollment  
• Failure to re -consent when new information is added  and approved  
• Use of a n outdated consent  
• Unqualified or non- delegated personnel perform consent process  
• Violation of inclusion/exclusion criteria  
• Failure to collect protocol required assessments procedures (e.g., VAS  data, subject assessment 
missing)  
• Missed visits  
• Visits outsid e of w indow  
• Missing source documentation  
• Use of expi[INVESTIGATOR_534519]  
• Use of drug(s) not allowed per the protocol (i.e. systemic opi[INVESTIGATOR_887530], 
cannabinoids, illicit drugs)  
• Addition of infusion drugs other that PFMS  
• Unauthorized personnel performing study procedures  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242279] has the right to withdraw from the study at any time and for any reason without prejudice to 
his/her future medical care by [CONTACT_978] [INVESTIGATOR_887531].  Subjects will be provided standard medical care by 
[CONTACT_534554] .  
The study sample size accounts for potential  attrition . Therefore,  subjects that discontinue after 
enrollment in th e study will not  be replaced.  
If a subject i s withdrawn from the study, the reason for withdrawal shall be recorded on a study exit 
eCRF and in the subject’s medical record.   
Examples of reasons for study discontinuation include, but are not limited to, the following:  
• Eligibility criteria not met  (prior to implant)  
• Pregnancy  
• Subject death  
• Subject lost to follow -up (LTFU)   
• Subject voluntarily withdraws from the study  
• Adverse events  
• Normal study completion  
A study exit e CRF must  be completed for any enrolled subject who permanently discontinues from the 
study regardless of whether they discontinue early or complete the protocol -required study follow -up 
and has completed the study.  
Study site personnel must make a minimum of three attempts to co ntact a subject before a subject can 
be considered LTFU for this study. Site personnel must document those attempts and the method of 
attempt (e.g. two by [CONTACT_534555])  to contact [CONTACT_887571]’s medical 
and/or study records. In addition, any other requirements set forth by [CONTACT_887572].  
The investigator should make all attempts to  conduct an in- office  discontinuation visit prior to subject 
withdrawal if  the subject is withdrawn after the device is imp lanted. All eCRFs should be completed for 
visits that occ urred prior to the subject’s withdrawal. In addition, regardless of when the discontinuation 
occurs, site personnel should request an update on the status of any medications, ongoing adverse event or  device deficiency . If a subject discontinues prior to completing the [ADDRESS_1242280].   Refer to the appropriate drug 
labeling for all current risks, contraindications, warnings, precautions, dosage and administration 
information and screening procedures. As such there is no increm ental risk associated with the 
participation in the  Embrace TDD Clinical Study.  
Systemic Opi[INVESTIGATOR_887532] : 
Investigators must review risks associated with systemic opi[INVESTIGATOR_887533]. Opi[INVESTIGATOR_887534]’s subjects current regimen of systemic opi[INVESTIGATOR_2438], and 
the method(s) utilized to assist with the weaning may impact any associated risks. Examples of 
withdrawal symptoms may include, but are not limited to the following:  
• Headache  
• Muscle aches, restless ness  
• Anxiety  
• Insomnia  
• Diarrhea  
• Nausea and vomiting  
• Rapid hea rtbeat  
 
Risks associated with Implantation or Use of an infusion system : 
• Pocket seroma, hematoma, erosion , or infection  
• Infection  
• Pump inversion (“flippi[INVESTIGATOR_007]”)  
• Placement of the catheter may expose p atients to risks of postlumbar puncture (spi[INVESTIGATOR_887535]), c erebral spi[INVESTIGATOR_872] ( CSF) leak and CSF subcutaneous collection or rare central 
nervous system (CNS) pressure -related problems, radiculitis, arachnoiditis, bleeding, spi[INVESTIGATOR_887536], or meningi tis 
• Inflammatory mass could result in neurological impairmen t, including paralysis  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 48 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  • Allergic or immune system response to the implanted materials. A listing of device materials can 
be found in the Device Specifications sections of the implant manuals for th e pump and 
catheters  
 
System - and Procedure -Related Complications : 
Possible system complications listed below can result in overdose symptoms, tissue damage, or a loss of 
or change in therapy, which might lead to a return of underlying symptoms, drug withdrawal symptoms, 
serious injury, or death and might require surgery to replace or remove the pump, catheter, or catheter 
fragment. These complications include:  
• End of device service life or component failure, requiring surgical replacement  
• Component failure , resulting in loss of t herapy, drug overdose, or inability to program the pump  
• The pump, catheter, or catheter fragment could migrate within the body or erode through the 
skin 
• The implanted materials could cause an allergic or immune system response  
• There  could be undesirable changes in therapy, possibly related to cellular changes around the 
tip of the catheter  
• An inflammatory mass that could result in serious neurological impairment, including paralysis  
• The catheter could leak, tear, or become disconnect ed, resulting in delivery of medication into 
the area under the skin where the pump is implanted or along the catheter path  
• The catheter could kink or become blocked resulting in no delivery of medication  
• The pump could stop because it has reached end of s ervice life or because o f a component 
failure  
• Catheter damage, dislodgement, migration, disconnection, kinking or occlusion, fibrosis, or hygroma, resulting in tissue damage or a loss of or change in therapy, and contributing to over infusion or other pote ntially serious adverse health consequences  
 
Risks of implanting an infusion system has risks similar to other surgical procedures, including pain or 
infection at the implant site after surgery. Implanting an infusion system that will deliver drug to a 
patient’s spi[INVESTIGATOR_050], has risks similar to spi[INVESTIGATOR_397533], including:  
• Pump implanted upside down  
• Improper handling of components before, during, or after implantation  
• Reservoir contamination  
• Improper injection through the catheter access port  
• Injection into the  pocket or subcutaneous tissue  
• Activation of the reservoir valve (if present)  
• Over pressurization of the reservoir, including by [CONTACT_887573]  
• Programming error 
• Tunneling during the catheter implant procedure may expose patients to risks of serious injury 
or death due to perforatio n of vital organs and/or major blood vessels  
• Detached catheter tip or catheter fragment(s) in the intrathecal space  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 49 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  • Residual catheter fragments may migrate, including rarely into the intracranial cavity, potentially 
resulting in ser ious adverse health cons equences that may require surgical removal  
• Residual catheter fragments in the CSF may compromise antibiotic effectiveness in the presence of a concomitant CSF infection  
 
Drug -Related Complications : 
• Local or systemic drug toxicity an d related side effects  
• Symptoms of overdose or underdose  
• Inflammatory mass formation at the tip of the implanted catheter particularly in patients who receive intraspi[INVESTIGATOR_887537] (s) for all cur rent  risks,  war nings, precautions and 
contraindications associated with the SynchroMed II infusion system. Product manuals are provided 
with the products  and are also av ailable electronically  at: 
http://manuals.medtronic.com/manuals/main/region
 
There may be other risks related to the SynchroMed II infusion system and/or PFMS used in this study 
that are not foreseen at this time. All anticipated adverse events are the same as those foreseeable risks listed in  Section [ADDRESS_1242281] notify  the study doctor immediately if they think they are pregnant or if they 
become pregnant dur ing the study. Site personnel are responsible for the following:   
• Documenting all  available  information regarding the pregnancy in the source documents and 
notifying Medtronic study personnel  
• Notifying  the IRB per the study site ’s requirements  
• Exiting the subject  from the study and completing  the appropriate eCRF(s) according to Section 
10.2 1 
 
11.3 Risk Minimization  (Control Measures)  
Each investigator must be familiar with the SynchroMed II infusion system and PFMS . The frequent 
monitoring of study subjects by [CONTACT_887574] . Each study center will have a staff of physicians and nurses experienced, educated, and trained to 
care for subjects implanted with a SynchroMed II infusion system . Medtronic will conduct study protocol 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 50 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  training for all study center personnel prior to study initiation . All study personnel will be provided with 
emergency instructions in the event an underdose or overdose of PFMS causes  life-threatening 
symptoms (Refer to the Technical Manual, “Indications, Drug Stability, and Emergency Procedure s for 
SynchroMed® and IsoMed® Implantable i nfusion s ystems” provided separately ). 
11.[ADDRESS_1242282] been developed to guide the use of 
infusion therapy with morphine for chronic intractable pain. Both the SynchroMed II infusi on system  
and PFMS are commercially available, with a positive risk- benefit ratio established for each . 
12. Adverse Events and Device Deficiencies  
 
12.1 Definitions / Classifications  
Any adverse event  (AE) meeting the definition of systemic opi[INVESTIGATOR_208781] -related , device- related , IT 
drug -related , and procedure -related, all serious adverse events and deaths (regardless of relatedness) 
for all subjects from Baseline to the 6 -Month Visit, and device deficiencies (DD) for all subjects from 
Implant to the [ADDRESS_1242283] -market study is not within the scope of ISO  [ZIP_CODE]:2011 but will use AE definitions according to 
ISO [ZIP_CODE]:2011 for consistency in reporting.  Each adverse event i s classified according to ISO 
[ZIP_CODE]:2011 . Adverse events and device deficiencies are defined below in Table 4 as follows:  
Table 4: Adverse Event and Device Deficiency Definitions  
Term  Definition  
Adverse Event (AE):  
(ISO [ZIP_CODE]:2011 3.2)  Any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in subjects, 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 51 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Term  Definition  
 users or other persons, whether or not related to the in vestigational medical 
device.  
NOTE 1:   This definition includes events related to the investigational 
medical device or the comparator.  
NOTE 2:  This definition includes events related to th e procedures 
involved.  
NOTE 3:  For users or other persons, this definition is restricted to 
events related to investigational medical devices.  
Adverse Device Effect 
(ADE):  
(ISO [ZIP_CODE]:2011 3.1)  Adverse event related to the use of an investigational medica l device.  
NOTE 1:  This definition includes adverse events resulting from 
insufficient or inadequate instructions for use, deployment, 
implantation, installation, or operation, or any malfunction of the 
investigational medical device.  
NOTE 2:  This definitio n includes any event resulting from use error or 
from intentional misuse of the investigational medical device.  
Device Deficiency 
(DD):  
(ISO [ZIP_CODE]:2011 3.15)  Inadequacy of a medical device with respect  to its identity, quality, 
durability, reliability, safety or performance.  
NOTE : Device deficiencies include malfunctions, use errors, and 
inadequate labeling.  
Malfunction:  
(ISO [ZIP_CODE]:2011 3.27)  Failure of an investigational medical device to perform in accordance with its 
intended purpose when used in acc ordance with the instructions for use or 
(CIP).  
Use Error:  
(ISO [ZIP_CODE]:2011 3.43)  
 Act or omission of an act that results in a different medical device response 
than intended by [CONTACT_3460].  
NOTE 1:  Use error includes slips, lapses, and mistakes.  
NOTE 2: An unexpected physiological response of the subject does 
not in itself constitute a use error .  
Term  Seriousness  
Serious Adverse 
Event (SAE):   
(ISO [ZIP_CODE]:2011 3.37)  
 Adverse event that  
a) led to death,  
b) led to serious deteriorati on in the health of the subject, that either 
resulted in  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, 
or 
3) in-patient or p rolonged hospi[INVESTIGATOR_059], or  
4) medical or surgical intervention to prevent life -threatening 
illness or injury or permanent impairment to a body structure or a body function,  
c) led to fetal distress, fetal death or a congenital abnormality or birth defect.  
NOTE:  Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure required by [CONTACT_10396], without serious deterioration in 
health, is not considered a serious adverse event.  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242284] (SADE):  
(ISO [ZIP_CODE]:2011 3.36)  Adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event  
Term  Relatedness  
Systemic Opi[INVESTIGATOR_887538] -Related  An adverse event related to the systemic opi[INVESTIGATOR_887539] (i.e. opi[INVESTIGATOR_2480] -
related withdrawal symptoms)  
Device -Related  An adverse event that results from the presence or performance (int ended 
or otherwise) of the SynchroMed II infusion system .  
IT Drug -Related  Event related to the IT drug deliver ed by [CONTACT_8121]. Normally IT drug -relat ed 
events resolve when the device is turned off or reprogrammed , or the drug is 
removed from the pump . This category should not include events that 
resulted from a malfunction of the device (i.e. hardware -related events).  
Procedure -Related  An adverse event that occurs due to any procedure related to the IT trial, 
implant , pump refills, programming , or surgi cal modification of the system.  
12.2 Reporting of Adverse Events  
Any AE  meeting the definition of systemic opi[INVESTIGATOR_208781] -related , device- related  (i.e. SynchroMed II 
infusion system) , IT drug -related , and procedure -related (i.e. IT trial, implant or pump 
refill/reprogramming, system modification) , and all serious adverse even ts and deaths  (regardless of 
relatedness), for all subjects from the Baseline Visit through  study exit will be collected.  
It is the responsibility of the investigator to identify the occ urrence of any reportable adverse events and 
to ensure all re quired information is accurately recorded in the subject’s medical record and reported to 
Medtronic on an event  eCRF. IRB reporting must be completed in accordance with the policies of the 
govern ing IRB . Refer  to the eCRF  for the information to be reported  for each AE.   
For AEs t hat require immediate reporting , initial reporting to Medtronic  may be done by [CONTACT_648], fax, or 
e-mail, or on the eCRF by [CONTACT_481408]. The  AE eCRF must be 
completed as soon as possible.   
In case the investigator requires information from the sponsor in an emergency , the investigator ca n 
contact [CONTACT_887575]  12.5. 
The clinical course of each AE must be followed until the adverse event is resolved, the subject is in a 
stable condition, or until the subject discontinues from the study. “Ongoing” AEs  must be assessed at 
each study visit.  The AE eCRF should be updated when there is a change to the information provided on 
the f orm ( e.g. change in intervention, outcome, relatedness,  etc.).  
At the last  study visit , the investigator will instruct the subject to provide an update on the status of any 
ongoing events and report any AE they believe may be related to participation in the study.     
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 53 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  12.3 Non-Reportable Events  
Examples of events that are not reportable as adver se events for this study include:  
• Inability to successfully perform a p rocedure, unless injury occurs  
• A documented pre -existing condition unless there is a worsening of the nature, severity, 
duration or frequency of that condition if it meets the defined c riteria for a reportable adverse 
event (i.e. systemic opi[INVESTIGATOR_208781], d evice, IT drug and/or procedure -related)  
Table [ADDRESS_1242285] -proce dure.  
Table 5: Expected Surgical Adverse Events and Durations  
Event Description  Timeframe After Su rgical 
Procedure  
Low-grade fever (˂ 100 ° or ˂37.8 ° C) 48 hours  
Anesthesia -related nausea/vomiting  24 hours  
Mild to moderate bruisin g/ecchymosis  7 days  
Pocket site / incisional pain  14 days  
Seroma  72 hours  
Sleep problems (insomnia)  72 hours  
12.4 Reporting of Device Deficiencies  
Device Deficiency (DD) information will be collected for all subjects from the Implant Visit through the [ADDRESS_1242286] regarding a SADE /DD, contact [CONTACT_534558].  
24-hour Medtronic contact [CONTACT_534559]/DD :  
Email:    
Fax:  
12.[ADDRESS_1242287] notify Medtronic immediately and the IRB ( as required ), after learning of a 
subject’s death ( regardless of relatedness) .  The death should be reported to Medtronic on the event 
eCRF as soon as possible. The investigator should also attempt to determine, as conclusively as possible, 
whether such deaths are related to the systemic opi[INVESTIGATOR_208781], device, IT drug,  or procedure .  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 54 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  If it is determined that the cause of death was related to systemic opi[INVESTIGATOR_208781], device, IT drug , or 
procedure:  
• A copy of an autopsy report should be provided to Medtronic, if an autopsy is performed  
• Medtronic requests that all device system components that were being used at the time of the 
death be returned to Medtro nic for analysis per S ection  7.11  
• Requested death certificates and/or source do cumentation if obtained, should be redacted and 
sent to Medtronic  
If the death occurs at a location remote from the study site, it i s the study site’s responsibility to make 
three  attempt s to retrieve all pertinent information related to the subject’s deat h and submit the 
investigator’s death summary of the known events surrounding the death to Medtronic . 
13. Data Review Committees  
This study will utilize a Clinical Events Committee (CEC ) to adjudicate the relatedness and seriousness 
classifications of all reportable adverse events.   
The CEC may request clarification and/or additional information from the PI [INVESTIGATOR_887540]. If 
the conclusion of the review differs from the PI’s assessment, both opi[INVESTIGATOR_248930]. Incidence rates will be tabulated using the final CEC determination.  
The CEC will be external to Medtroni c and independent of the study i nvestigators. The members will 
have specialties appropriate to the therapeutic area and meet requirements established in the CEC charter.  
14. Statistical Design and Methods  
14.1 General Aspects of Analysis  
Data analysis will be perf ormed by [CONTACT_13735] -employed statisticians or designees. A validated statistical 
software packag e will be used for the analyses of the study results (e.g. SAS  version 9.4 or higher ). 
The Statistical Analysis Plan (SAP) will be developed prior to data analys is and will include a 
comprehensive description of the statistical methods and reports to be in cluded in the final study 
report. Any change to the data analysis methods described in the CIP will require an amendment only if 
it changes a principal feature of the CIP. Any other change to the data analysis methods described in the 
CIP, and the justification for making the change, will be described in the clinical study report.  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242288] the secondary objective related to pain 
score.   
There were no available data in the target population on the primary objective of Clinical Success, nor on the secondary objective of opi[INVESTIGATOR_2480] -related side effects  score. The secondary objective of pain intensity 
score is used for sample size calculation. It  is hypothesized that the pain intensity score of VAS at the 6 -
Month Visit  is non- inferior to those at B aseline using a non -inferiority approach.  
The PASS  11 Non -Inferiority Tests for One Mean was used to calculate the power  for pain intensity of 
VAS with the following assumptions: Sample size = 50, Alpha = 0.025, Non -Inferiority Margin = 1, True 
Difference = 0, Standard Deviation = 1. 9, with Higher Means are Better (one- sided) t -test. A sample size 
of 50 would achieve 95% power with the above assumptions. This power calculation was performed using a pain scale of 0 -10; however, the power calculation is identical to one with a non- inferiority 
margin of [ADDRESS_1242289] deviation of 19 on a VAS pain scale of 0 -100.  
The non- inferiority margin of 1 0 points (for the VAS of 0 -100)  was chosen based on a review of pain  
study literature. Non -inferiority margins between 1 and 1.5 were reported for pain scale s of 0 -10, 
including one study in a similar population of chronic non- malignant pain subjects comparing 2 oral 
opi[INVESTIGATOR_887541] a margin of 1
d. The non- inferiority margin of 1 on a pain scale of 0 -10 is equivalent 
to a non -inferiority margin of 10 on a VAS pai n scale of 0 -100. The estimated actual difference was 
assumed to be 0 because the goal is to achieve same or better pain control as compared to Baseline. 
 
 
 
 
 
  
A 33% attrition between enrollment and subject implant is assumed and a 25% attrition between Implant and the 6 -Month Visit is assumed. Under CIP V2.0, approximately 100 subjects were to be 
enrolled; [ADDRESS_1242290] been enrolled into the study with the intent to achieve approximately 67 implanted subjects and 50  eval uable subjects at the 6 -Month Visit .  
 
d Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R.  A randomized study to demonstrate noninferiority of once -daily 
OROS ® hydromor phone with twice- daily sustained -release oxycodone for moderate to severe chronic noncancer pain, Pain Pract.  
2010;10(5):404 –415. 

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 56 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  The 33% attrition between enrollment and subject implant accounts for the subjects who don’t meet 
inclusion and/or exclusion criteria, those who can’t follow the weaning process to eliminate systemic 
opi[INVESTIGATOR_2438], thos e who  don’t have a successful IT trial, those who have AE that can no longer be followed in 
the study, withdrawals, and lost -to-follow -up, etc. The attrition between implant and the 6 -Month Visit 
is conservatively set at 25% to potentially account for the subje cts who have adverse events that can no 
longer be followed in the study, withdrawals, are LTFU, or subjects who can’t be effectively managed on morphine monotherapy.  
14.1.[ADDRESS_1242291] study data. The site study personnel will be trained prior to the study initiation at each site. Periodic study monitoring by [CONTACT_865391].  
There is n o a p riori provision to exclude any sites from the analysis. The data from all sites will be pooled 
for analysis. To reduce the possibility of atypi[INVESTIGATOR_481353] a site overly influencing the combined 
results, no more than 15 subjects will be enrolled a t eac h site  unless the site gets pre- approval from the 
Medtronic for additional enrollments .  
14.1.3  Other Specific Considerations  
Adjustment for Baseline Covariates  
There is no plan to make adjustment for B aseline covariates for the primary objective.  
Handling Missing Data  
Missing data are a potential source of bias when analyzing study data. A rigorous study design and 
execution will help prevent the incidence of missing data from occurring.  
The primary a nalysis of the primary and secondary objectives will include  subjects who maintain 
morphine monotherapy and provide data (per -protocol population).  Sensitivity analyses will be 
performed for the primary and secondary objectives using the Multiple Imputatio n (MI) methodology 
for missing data in VAS and NOSE scor es for all implanted subjects. Details of the imputation method are 
described in Sections 14 .4.1 and 14 .4.2. 
Adjustment for Multiple Endpoints  
As there is no hypothes is testing  for the primary objective , adjustment for multiple endpoints i s not 
required.  
Interim Analysis  
There is no planned interim analysis for the primary and secondary objectives in this study.  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 57 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  14.1.4  Reports  
A final clinical study report will be generated for this study. Periodic progress reports may also be 
generated for the study . 
14.2 Demographics  
Demographics and B aseline characteristics will be summarized in the report for enrolled subjects, 
implanted subjects , and per -protocol subjects for the primary obje ctive.  
14.3 Primary Objective  – Clinical Success at the 6 -Month Visit  
To characterize the proportion of subjects with Clinical Success at the 6 -Month Visit  based on changes in 
pain intensity using the Visual Analog Scale (VAS) and changes in opi[INVESTIGATOR_2480] -related sid e effects using the 
Numer ical Opi[INVESTIGATOR_887496] (NOSE) Assessment Tool.  
Hypothesis  
There is no formal hypothesis. The objective is to estimate the proportion of Clinical Success at the 6 -
Month Visit.  
Experimental Design  
The Clinical Success is comprised  of 2 separate measures, pain intensity and opi[INVESTIGATOR_2480] -related side effects . 
The measurements of pain intensity using VAS and opi[INVESTIGATOR_2480]- related side effects using NOSE are described 
in Sections 10.1 7.1 and 10.1 7.2. Both pain intensity and opi[INVESTIGATOR_2480]- related side effects are measured as a 
percent change from Baseline to the 6 -Month Visit to calculate the Clinical Success.  
Pain I ntensity:  
Percent change in pain intensity will be calculated as VAS at the [ADDRESS_1242292] percent change in pain 
intensity is categorized into three  responder groups at the 6 -Month V isit: 
• Worse than Baselin e: percent of change in VAS ≥ 20% (increased equal or more than 20%) if 
Baseline VAS is ≥10 or change in VAS is ≥ 2 if Baseline VAS is < 10  
• Equal to Baseline: percent of change in VAS < 20% and > - 20% (increased less than 20% or 
decreased less than 20%) if  Baseline VAS is ≥10 or change in VAS is between -2 and 2 if Baseline 
VAS is < 10  
• Better than Baseline: percent of change in VAS ≤ -20% (decreased equal or more than 20%) if 
Baseline VAS is ≥10 or change in VAS is ≤ -2 if Baseline VAS is < 10  
 
Opi[INVESTIGATOR_2480] -Relat ed Side Effects:  
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242293] percent change in NOSE  is 
categorized into three  responder groups at the 6 -Month Visit : 
• Worse than Baseline: percent of change in NOSE ≥ 20% (increased equal or more than 20%)  if 
Baseline NOSE is ≥10 or change in NOSE is ≥ 2 if Baseline NOSE is < 10  
• Equal to Baseline: percent of change in NOSE < 20% and > - 20% (increased less than 20% or 
decreased less than 20%) if Baseline NOSE is ≥10 or change in NOSE is between - 2 and 2 if 
Baseline NOSE is < 10  
• Better than Baseline: p ercent of change in NOSE ≤ -20% (decreased equal or more than 20%) if 
Baseline NOSE is ≥10 or change in NOSE is ≤ - 2 if Basel ine NOSE is < 10  
 
Clinical Success:  
A subject’s Clinical Success is defined as any of the following and displayed in Figure 2 : 
1. Reduced opi[INVESTIGATOR_2480] -related side effects  with equal pain  
2. Reduced pain with equal opi[INVESTIGATOR_2480] -related side effects  
3. Reduced pain and reduced opi[INVESTIGATOR_2480] -related side effects  
Figure 1: Clinical Success  
Change  
from Baseline  
to the 6 -Month Visit   Opi[INVESTIGATOR_2480] -Related Side Effects  
(NOSE ) 
≥20% 
Increase  < ±20% 
Change  ≥20% 
Reduction  
Worse  Equal  Better  Pain Intensity (VAS)  ≥20% 
Increase  
Worse  
      
< ±20% 
Change  
Equal  
    1  
≥20% 
Reduction  
Better  
   [ADDRESS_1242294] binomial two -sided 95% confidence 
interval will be reported. The primary analysis method will use all the implanted subjects who maintain 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 59 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  morphine monotherapy  and provide data at both B aseline and the 6 -Month Visits (per -protocol 
population) . Assum ing the estimated proportion of Clinical Success is 70%, with  a sample size of [ADDRESS_1242295] two- sided 95% confidence interval (CI) would be 55.4- 82.1% , with a confidence width 
of 26.7%. The w idest 95% CI would be at 28.9% for an estimated proportion of Clinical Success of 50% 
(95% CI 35.5- 64.5%).  
Two sensi tivity analyses will be performed: t he proportion of subjects with Clinical Success and its 95% 
CI will be reported in subjects who provide data at the 6 Month Visit (completers) as well as in all 
implanted subjects with imputation method of MI for those w ho has missing VAS or NOSE at the 6 -
Month Visit . Details of the imputation method are described in Sections 14 .4.1 and 14 .4.2. 
14.4 Secondary Objective s 
There are three se condary objectives in the study.  
14.4.1  Secondary Objective #1 – VAS Pain Intensity at the 6 -Month Visit  
To demonstrate pain intensity scores (VAS) at the 6 -Month Visit is non- inferior to  VAS at B aseline.   
Hypothesis  
The mean change in pain intensity using VAS f rom Baseline to the 6 -Month Visit is not worse than 0 by 
[CONTACT_726] 10 points .  
H0: μ ≥ 0 + |M|  
HA: μ < 0 +|M|  
Where μ is the mean change in VAS from Baseline to the 6 -Month Visit  and |M| is the absolute value of 
non-inferiority margin of 10. 
Experimental Design  
The measurements of pain intensity using VAS is described in Section 10.1 7.1. The change in VAS is  
calculated using VAS at the 6 -Month Visit minus VAS at the Baseline Visit. A negative change is an 
improvement.  
Analysis Methods  
The change in VAS as well as VAS at both Baseline and the 6- Month Visit will be summarized using 
descriptive statistics, (e.g., mean, standard deviations, etc.). The non- inferiority null hypothesis will be 
tested using a one- sided 0.[ADDRESS_1242296]. The upper  bound of the 95% CI of the 
mean change must be less than 10. If non -inferiority is met, a two -sided 0.[ADDRESS_1242297] for 
superiority (vs. 0 change from Baseline) will be performed. If the distribution of the change in VAS 
doesn’t meet normality assumption, an appropriate non- parame tric analysis will be performed. The 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 60 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  primary analysis will use all the implanted subjects who maintain morphine monotherapy and provide 
data at both Baseline and 6 -Month Visits.  
Two sensitivity analyses will be performed, one will include subjects who prov ide data (completers) and 
one will include all implanted subjects. The sensitivity analysis of all implanted subjects will be 
performed using MI method for missing data at the [ADDRESS_1242298]  age, gender, primary 
diagnosis, VAS at Baseline, 1 -Month Visit,  3-Month Visit. The fully conditional specification method with 
10 burn- in iterations within SAS and 10 repetitions (M = 10) will be used for imputation. Constraints will 
be set so that the im puted VAS are restricted to values ranging from 0 -100. Following  imputation, the 
objective will be evaluated using MI analysis method.  
In addition, percentage of change in VAS will be calculated using change in VAS divided by [CONTACT_887576]. A negative p ercentage of change in VAS is a percentage of reduction in VAS, thus an 
improvement. The percentage of change in VAS will be summarized using descriptive statistics, (e.g., median and inter -quartile range)  
14.4.2  Secondary Objective #2  – NOSE Score  
To characterize the change in opi[INVESTIGATOR_2480] -related side effects scores ( NOSE)  from B aseline to the 6 -Month 
Visit.  
Hypothesis  
There is no formal hypothesis. The objective is to estimate the change in NOSE  from B aseline to the 6 -
Month Visit .  
Experimental Design  
The measurements of opi[INVESTIGATOR_2480] -related side effects NOSE are described in Section 10.1 7.2. The change in 
NOSE is calculated using N OSE at the 6 -Month Visit  minus NOSE at Baseline. A negative change is an 
improvement.  
Analysis Methods  
The change in NOSE will be summarized using descriptive statistics, (e.g., mean, standard deviations, etc.). The analysis will use all the  implanted  subjects who maintain morphine monotherapy and provide 
data at both B aseline and the 6 -Month Visits. 
Two sensitivity analyses will be performed, one will include subj ects who provide data (completers) and 
one will include all implanted subjects. The sensitivity analysis of all implanted subjects will be 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242299] age, gender, primary diagnosis, 
NOSE at Baseline, 1- Month Visit, 3 -Month Visit. The fully conditional specification method with 10 burn-
in iterations within SAS and 10 repetitions (M = 10) will be used for imputation. Constraints will be set so 
that the imputed NOSE are restricted to values ranging from 0 -100. Following imputation, the objective 
will be evaluated using MI analysis method.  
In addition, percentage of change in NOSE will be calculated using change in NOSE divided by [CONTACT_887577]. A negative percentage of change in NOSE is a percentage of reduction in NOSE, thus an 
improvement. The percentage of change in NOSE will be summariz ed using descriptive statistics, (e.g., 
median and inter -quartile range, etc.).  
14.4.3  Secondary Objective #3 – Systemic Opi[INVESTIGATOR_887542] [ADDRESS_1242300] binomial two -sided 95% CI will 
be reported  at the 6 -Month Visit as well as for those having eliminated systemic opi[INVESTIGATOR_887543] 6 -Month Visit . The primary analysis method will use al l the implanted subjects 
who maintain morphine monotherapy and provide  data at the 6 -Month Visit . Assume the estimated 
proportion is 8 0%, with a sample size of [ADDRESS_1242301] two- sided 95% CI would be 66.3- 90.0%, 
with a confidence width of 23.7%.  The widest 95% CI would be at 28.9% for an estimated proportion of 50% (95% CI 35.5- 64.5%).  
Two sensitivity analyses will be performed, one will include subjects who provide data (completers) and 
one will include all implanted subjects. The sensitivity analysis in all implanted subjects’ analysis will 
display the full range on the potential impact of missing data by [CONTACT_887578]18026  Version  3.0 Page 62 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  values had eliminated sys temic opi[INVESTIGATOR_887544] s.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
14.6 Safety Assessment  
To characterize all  systemic opi[INVESTIGATOR_208781] -related, device- related, IT drug -related,  and procedure -
related adverse events (AEs), all serious adverse events (SAEs) ( regardless of relatedness), and device 
deficiencies (DD) for all  subjects from enrollment until the subject exits . 
15. Ethics  
15.1 Statement(s) of Compliance  
This study will be conducted in compliance with this CIP and Good Clinical Practices according to the 
Unite d States (US) Code of Federal Regulations (CFR) on Electronic records (21 CFR§11), Protection of 
Human Subjects (21 CFR§50), Institutional Review Boa rds (21 CFR §56), Medical Device Reporting 
(21CFR§803), International Conference on Harmonization (ICH GCP E6) the ethical principles that 

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 63 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  originate from the Declaration of Helsinki, and applicable local regulatory requirements and laws in the 
states in wh ich the study will be conducted. This  study  is posted on http://www.ClinicalTrials.gov  
([STUDY_ID_REMOVED])  as part of Medtronic’s commitment to full disclosure for ongoing studies that meet the 
requirements for public posting.  
The principles of the Declaration of Helsinki have been implemented through the patient informed 
consent process, IRB  approval, study training, clinical trial registration, preclinical testing, risk -benefit 
assessment and publication policy.  
Prior to enrolling subjects in this study, each study site’s IRB will be required to approve  the current CIP 
or CIP amendments , the  subject ICF/HIPAA, including any other written information to be provided to 
the subjects and, if applicable, any materials used to recruit subjects. IRB approval letters must contain 
sufficient information to identify  the version and/or date of the docum ents that were approved, or the 
information must be retrievable from the corresponding submission letter. Sites must also receive 
written approval of activation from Medtronic prior to initiating subject enrollments.  
Investigators will be required to sign a Statement of Investigator Commitment form stating their intent 
to adhere to applicable regulations.  
The sponsor shall avoid improper influence on, or inducement of, the subject, monitor, any 
investigator(s) or other p arties participating in, or contribut ing to, the clinical investigation. All 
investigators shall avoid improper influence on or inducement of the subject, sponsor, monitor, other 
investigator(s) or other parties participating in or contributing to the clinical investigation.  
16. Study Administrat ion 
16.[ADDRESS_1242302] of this study in terms of adherence to 
applicable regulations, protocol compliance, and the validity and accuracy of the study data entered on 
eCRF s.  As such, investigational sites wi ll be monitored to ensure the safety and well -being of study 
subjects is preserved, and to ensure site compliance with the study protocol, applicable regulations, and IRB requirements to ensure study data is accurate and complete.  
Monitoring and monitoring oversight will be provided by [CONTACT_534564] (i.e. contractors and other designees) who will support the study investigation including site 
qualification, site initiation, inter im monitoring , and study closure visi ts. 
Contact [CONTACT_249018] : 
 

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242303] access to source 
data (e .g., paper and electronic hospi[INVESTIGATOR_307]/clinical charts, appointment books, laboratory records) that 
support the data on the eCRFs , as well as other documentation supporting the conduct of the study.  
Monitors will perform sou rce data verification  and routine rev iews of study -related regulatory 
documents during scheduled monitoring visits and work to secure compliance should any deficiencies 
be observed. The monitoring plan contains the strategy for frequency of monitoring visits and source 
data verification to be  performed for this study.  
It is an expectation that the PI [INVESTIGATOR_887545].  
16.[ADDRESS_1242304]’s needs during an activity performed by a Medtronic 
representative.  
Medtronic representatives may  provide technical support to the investigator and other health care 
personnel as needed during study visits.  This support may include the training of site personnel on use of the Medtronic equipment or the protocol -related procedures and data collection.  
In addition, Medtronic personnel may perform certain activities to ensure study quality.  These activities may include:  
• Provide technical support du ring IT trial , implant , and follow -up visits  
• Perform device programming, while under the direction of the investigator  or study site 
personnel delegated responsibility for device programming  
• Discuss any issues with prog ramming or subject compliance with the PI [INVESTIGATOR_887546]   
• Clarify and/or troubleshoot device behavior, operation, or diagnostic output as requested by [CONTACT_1600] [INVESTIGATOR_887547]  
• Perform device interrogatio n, printing or uploading of device information while under the 
direction of the investigator or study site personnel delegated responsibility for the collection of study data from equipment and upload into the NPU database  
 
Medtronic personnel may not perf orm the following:  
• Practice  medicine provide medical diagnoses or make decisions related to subject 
treatment/care  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 65 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  • Discuss a subject’s condition or medical treatment with the subject or a member of the subject’s  
family  
• Express opi[INVESTIGATOR_887548]/feature under study  
• Assist the  subject by [CONTACT_481413] -related 
task to be conducted  
• Provide the subject with any form/questionnaires related to the products under investigation  
• Enter data on eCRFs, with the exception of the Medtron ic Use Only fields/forms  
  
16.3 Data Management  
This study will  use the Oracle Clinical RDC system, which allows the study centers to enter data directly 
on the eCRF with in the sponsor’s database over a secure internet connection. Th is system is a fully 
validat ed system and 21CFR§11 Part  E compliant. The RDC system controls user access, ensures data 
integrity, and maintains an audit trail  of entries, changes and corrections made to the eCRFs. User access 
will be granted by [CONTACT_887579] a site based upon his or her delegation of 
authority for the study and only upon completion of the required training. The investigator and 
applicable study site personnel will be given access to the electronic eCRF system; u ser IDs and 
passwords may no t be shared.  
The PI [INVESTIGATOR_887549] , accuracy  and timeliness  of the data entered on the eCRFs 
and the data in all other required reports.  The PI [INVESTIGATOR_11637] -investigator (physician only) must  review all 
data for accuracy and provide his/her  approval of the eCRF and sign each form with an electronic 
signature. Data reported on the eCRFs, must be derived from and consistent with source documents , 
unless otherwise stated in this section or the st udy monitoring plan. If discrepancies in source a re 
identified during monitoring, these need to be corrected or a justifi cation noted  with a documented 
rationale, and then signed and dated by [CONTACT_978] , or authorized delegate, to be maintained as a part of th e 
subject’s records . If a person only authorized to complete eCRFs makes changes to an already signed 
eCRF, the system will require the PI , or authorized delegate, to re- sign the eCRF.  
The eCRF may be considered the source for the following data collection  elements:  
• Investigator assessment of adverse eve nt relatedness and seriousness  
• Details pertaining to and reason for protocol deviation  
 
Even when the eCRF may be considered as source (as noted above), an alternative method of source 
documentation is always strongly encouraged.  
Medtronic personnel will perform routine edit and consistency checks, internally  and during monitoring 
visits, for items such as missing data or inconsistent data.  Identified data inconsistencies will be 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 66 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  resolved by [CONTACT_887580] ; investigators a nd site personnel will review 
data discrepancies  and respond to them in a timely manner. The resolved discrepancy will become a 
part of the eCRF record for the subject.  
At the end of the study, the eCRF dat a will be frozen  (locked) and will be retained indefinitely by 
[CONTACT_13735].  Each subject’s device programmer interrogation data will be stored in the NPU database.  
16.[ADDRESS_1242305] Access to Source Data/Documents  
Source documentation is defined as the original documents, data and records and may include all  
clinical  records, hospi[INVESTIGATOR_1097], laboratory notes, surgery reports, autopsy reports, and other 
documents,  electronic or paper, that contain original informat ion to support study data collections or AE  
reporting. The PI [INVESTIGATOR_534530], legible , and accurate; 
and entries are made in a timely manner by [CONTACT_887581] .   
The PI [INVESTIGATOR_534531](s) with direct access to source 
documentation  or certified copi[INVESTIGATOR_887550] s the data on the eC RFs as well as other documentation 
supporting the conduct of the study.   
Medtronic or third- party auditors representing Medtronic may perform clinical site  audits to verify the 
performance of the monitoring process , study conduct, and to ensure compliance  with applicable 
regulations. Representatives f rom regulatory bodies such as the FDA may also perform site inspections 
related to this clinical study.  The PI , site personnel, and institution will provide monitors, auditors, and 
FDA with direct access to source d ocumentation and all study -related documentation.  
Medtronic will investigate  all suspected cases of fraud or misconduct as appropriate.  
16.[ADDRESS_1242306] identification code (study - site - 
subject number) will be assigned and used to allow identification of all data reported to Medtronic for each subject. Subject confidentiality is assured through use of the study -specific subject identification 
numbers, use of initials only, and the de -identifying of sub jects’ records obtained by o r provided to the 
Sponsor.  
For purposes of monitoring this study, access to clinic and hospi[INVESTIGATOR_865375], representatives of Medtronic (i.e. contractors and other designees) , the FDA and other 
regulatory agencies.  Study data  may be made available to third parties (e.g., in the case of an audit or 
inspection performed by [CONTACT_12721]), provided the data are treated confidentially and the 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.[ADDRESS_1242307]’s privacy is guaranteed. The identity of a s ubject will never be disclos ed in the event study data 
are published. Only anonymized data will be analyzed and published.  
In addition to the review of records at the center, release of de- identified records to Medtronic m ay be 
necessary . The investigational site personnel must make every effort to de -identify and label source 
documentation with the subject’s study -specific identification number prior to submission of the records 
to Medtronic.  
Health Insurance Portability and Accountability Act (HIPAA) language will be required to be included at 
every center. HIPAA language may be included within the ICF, or separately,  according to the center’s 
policy.  
16.[ADDRESS_1242308] will be documented in a 
separate financial agreeme nt signed by [CONTACT_13735], the PI , and/or  the management of  the study 
site/institution.  
16.[ADDRESS_1242309] igator Records  
Documentation for this study will be produced and maintained to ensure that a complete history of the study exists.  Documents created for this study, including all versions of original documents, will be identifiable and appropriately stored to assure control and traceability of data related to this study.  
The PI [INVESTIGATOR_887551] a minimum of 2 years (or longer as local law or facility  administration requires) a fter the investigation is 
terminated or completed .  The retention period may be longer if required by [CONTACT_13735] , local or global 
regulatory requirements. Medtronic will be responsible for notifying sites of extensions to the [ADDRESS_1242310] deaths, deviations from the CIP. In addition, investigators are also responsible for maintaining all 
correspondence with another investigator, an IRB, the spon sor, a monitor, or FDA, related to this study 
(including approval documentation), r ecords of each subject’s case history and exposure to the device 
(including signed and dated informed consent forms & HIPAA authorizations , as well as source 
documentation of the consent process ), final report, and all other study -related documentation.  
16.8.2  Investigator Reports  
The PI [INVESTIGATOR_481385] (review and signature) and submission to the sponsor of all case report forms, adverse events, device deficiencies, deaths, and any deviations from the CIP. If any action is taken by [CONTACT_93000], copi[INVESTIGATOR_169247] a timely manner. Reports are subject to inspection and to the retention 
requirements as described above for investigator records.  
Investigator reporting requirements for termination or suspension are listed in Section 16 .10. The 
investigator shall prepare and submit in a complete, accurate and timely manner the reports listed in this section.  
16.9 Publication and Use of Information  
It is intended that study r esults will be published in scientific literature.  Information provided related to 
patent applications, technical design, or manufacturing processes supplied to the investigator as a part 
of the investigational plan is considered confidential and is not to  be included in publications without 
the consent o f Medtronic. If required by a publisher, the PI [INVESTIGATOR_887552] -related information for publication. Specific requirements 
regardi ng publication of study data will be provided in t he study center  agreement and in the 
publication strategy.  
16.9.1  Publication Committee  
Medtronic will form a publication committee to develop a publication strategy and to oversee the development and review of pu blications related to the study. The publication committee may include 
representation from physician study advisors , the designated  participating investigators, and Medtronic. 
The publication committee will be responsible for overseeing and ensuring that the publication strategy 
is executed according to the established plan. Publication committee membership does not guarantee 
or provi de privileges in terms of authorship.  
The publication committee members will be responsible for reviewing all primary and secondary 
manuscripts prior to submission to the target journal and for reviewing abstracts prior to submission to conferences. In addition, publication committee members w ill review and approve requests for 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 69 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  secondary (ancillary) multicenter publications not included in the publication strategy. Requests will be 
reviewed to determine scientific validity, potential conflicts with previously  submitted publications, and 
the nee d for Medtronic  resources.  
16.9.[ADDRESS_1242311] and Reporting of Research as defined by 
[CONTACT_4717] ( http://www.ic mje.org ). 
16.[ADDRESS_1242312]’s devices wi ll be programmed as per the investigator’s discretion 
and once exited from the study, sub jects will be managed by [CONTACT_9682].  
16.10.1  Study -Wide Termination or Suspension  
Medtronic reserves the right to suspend or terminate the study at any time.  R easons may  include, but 
are not limited to, the following:  
• Insufficient enrollment to complete the study within the expected timeframe  
• Identification of adverse events or safety issues with the product or system that may impact the 
safety or welfare of study subjects  
• Product performance/product supply issues  
16.10.2  Investigator/Center Termination or Suspension  
Medtronic reserves the right to suspend or terminate the study at an individual site.  Reasons may 
include, but are not limited to, the following:  
• Noncomplianc e with the protocol  
• IRB approval lapse/expi[INVESTIGATOR_1516]  
• Serious or repeated deviations at the site  
• Failure to implement required corrective and preventive actions  
• Insufficient enrollment to complete the study within the expected timeframe  
• Loss of appropriately trained site personnel  
• Investigator request (e.g. no longer able to support the study)  
 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 70 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Investig ators are required to notify the IRB of study suspension/termination.  Subjects will be notified by 
[CONTACT_534571]/termination due to unacceptable risk or of termination due to any other 
cause . 
17. References  
1.  Wang JK, Nauss LA, Thomas JE. Pain relief by [CONTACT_887582]. 
Anesthesiology . 1979;50(2):149- 51. 
2.  Onofrio BM, Yaksh TL, Arnold PG. Continuous low -dose intrathecal morphine administration in 
the treatment of chronic pain of malignant origin. Mayo Clin Proc . 1981;56(8):516- 20. 
3.  Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implan table drug delivery 
system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug -related toxicity, and sur vival. J Clin Oncol . 2002;20(19):4040- 9. 
4.  LS S. Relieving pain in America: A blueprint for transforming prevention, care, education, and research. 2012.  
5.  Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference-- 2012: consensus on 
diagnos is, detection, and treatment of catheter -tip granulomas (inflammatory masses). 
Neuromodulation. 2012;15(5):483- 95; discussion 496.  
6.  Allen JW, Horais KA, Tozier NA, et al. Time course and role of morphine dose and concentration in intrathecal granuloma f ormation in dogs: a combined magnetic resonance imaging and 
histopathology investigation. Anesthesiology . 2006;105(3):581- 9. 
7.  Allen JW, Horais KA, Tozier NA, Yaksh TL. Opi[INVESTIGATOR_887553]. Anesthesiology . 2006;105(3):590- 8. 
8.  Yaksh TL, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ. Inflammatory masses associated with  intrathecal drug infusion: a review of preclinical evidence and human data. Pain 
Med . 2002;3(4):300- 12. 
9.  Staats PS, Yearwood T, Charapata SG, et  al. Intrathecal ziconotide in the treatment of refractory 
pain in patients with cancer or AIDS: a randomize d controlled trial. JAMA. 2004;291(1):63- 70. 
10.  Rauck RL, Wallace MS, Leong MS, et al. A randomized, double -blind, placebo -controlled study of 
intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage . 
2006;31(5):393- 406.  
11.  Wallace MS, Charapata SG, Fisher R, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double -blind, placebo -controlled clinical trial. 
Neuromodulation. 2006;9(2):75- 86. 
12.  Hamza M, Doleys D, Wells M, et al. Prospe ctive study of 3 -year follow -up of low -dose intrathecal 
opi[INVESTIGATOR_887554]. Pain Med . 2012;13(10):1304- 13. 
13.  Grider JS, Etscheidt MA, Harned ME, et al. Trialing and Maintenance Dosing Using a Low -Dose 
Intrathecal Opio id Method for Chronic Nonmalignant Pain: A Prospective 36 -Month Study. 
Neuromodulation. 2016;19(2):206- 19. 
14.  Smith TJ, Staats PS, Deer T, et al. Rand omized clinical trial of an implantable drug delivery 
system compared with comprehensive medical managem ent for refractory cancer pain: impact 
on pain, drug -related toxicity, and survival. J Clin Oncol . 2002;20(19):4040- 9. 
Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 71 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  15.  Hamza M, Doleys DM, Saleh IA , Medvedovsky A, Verdolin MH, Hamza M. A Prospective, 
Randomized, Single -Blinded, Head- to-Head Long -Term  Outcome Study, Comparing Intrathecal 
(IT) Boluses With Continuous Infusion Trialing Techniques Prior to Implantation of Drug Delivery 
Systems (DDS) for  the Treatment of Severe Intractable Chronic Nonmalignant Pain. 
Neuromodulation. 2015;18(7):636- 48; disc ussion 649.  
16.  Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by [CONTACT_282846] (intraspi[INVESTIGATOR_1304]) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15(5):436- 64; discussion 464 -6. 
17.  Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusio n Systems Best Practices and Guidelines. 
Neuromodulation. 2017;20(2):96- 132.  
18.  Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks. Neuromodulation. 2017;20(2):155- 176.  
19.  Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Co nsensus Conference (PACC): 
Recommendations for Trialing of Intrathecal Drug Delivery Infusion Therapy. Neuromodulation. 2017;20(2):133- 154.  
20.  Prager J, Deer T, Levy R, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17(4):354- 72; discussion 372.  
21.  Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations for Trialing of Intr athecal Drug Delivery Infusion Therapy. Neuromodulation. 
2017;20(2):133- 154.  
22.  Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines. Neuromodulation . 2017;20(2):96- 132.  
23.  Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conferen ce (PACC): 
Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks. Neuromodulation. 2017;20(2):155- 176.  
24.  Dunn KM, Saunders KW, Rutter CM, et al. Opi[INVESTIGATOR_378558]: a cohort stu dy. Ann Intern Med. 2010;152(2):85- 92. 
25.   
 
18. Appendices  
18.1 Appendix A: Additional Information for Sites  
Detailed sponsor contact [CONTACT_887583] a separate cover . 
18.2 Appendix B: Institutional Review Boards  
The table below represents all IRBs that were active at any time during the study. Infor mation contained 
in this table is subject to change and will not require CIP revision.  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 72 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  IRB Name  [CONTACT_887585]/ Chair  
WIRB Copernicus Group (WCG) IRB  [ADDRESS_1242313]., S E 
Suite 120 
Puyallup, WA [ZIP_CODE]   
Eastern Virginia Medical School Office 
Research IRB*  [ADDRESS_1242314].  
Galveston, TX [ZIP_CODE]  
Lehigh Valley Health Network IRB * [ADDRESS_1242315].  
Suite 3200 
Allentown, PA [ZIP_CODE]  
* Study was closed with the IRB under CIP V2.0  
18.3 Appendix C : Participating Principal Investigators and 
Institutions  
The table below represent s all sites that were activated for participation, regardless of if they enrolled 
subjects or not.  
Investigator Name  [CONTACT_16277] / Site Name  [CONTACT_887586], WA  [ZIP_CODE]  
 Premier Pain Treatment 
Institute   
Mount Orab, OH [ZIP_CODE]  
 Coastal Pain and Spi[INVESTIGATOR_887555], CA [ZIP_CODE]  
* University of Virginia Pain 
Management Center   
  
Charlottesville, VA [ZIP_CODE]  
 Regional Brain & Spi[INVESTIGATOR_887556], MO [ZIP_CODE]  
 The Pain Management Center     
 
Voorhees, NJ 080 43 

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 73 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  Investigator Name  [CONTACT_16277] / Site Name  [CONTACT_63754]  
* University of [LOCATION_007] Medical 
Branch   
Galveston, TX [ZIP_CODE]- [ADDRESS_1242316]. Louis, MO [ZIP_CODE]  
* Lehigh Valley Health Network 
Office of Research and 
Innovation    
  
Al
lentown, PA [ZIP_CODE] 
* Eastern Virginia Medical School    
   
No
rfolk, VA [ZIP_CODE]  
 Comprehensive and 
Interventional Pain Management    
 
Hend
erson, NV [ZIP_CODE] 
 Moss Rehab - Einstein 
Healthcare Network   
Elkins Park, PA [ZIP_CODE] 
 [LOCATION_012] Pain Institute Merritt 
Island    
 
Mer
ritt Island, FL [ZIP_CODE] 
 Precision Spi[INVESTIGATOR_887557], TX [ZIP_CODE] 
 Napa Valley Orthopaedic 
Medical Group   
 
Napa
, CA [ZIP_CODE]  
 Neuroversion   
 
Anch
orage, AK [ZIP_CODE] 
* Site closed under CIP V2.0  
  

Embrace TDD Clinical Investigation Plan  
 Form  
MDT18026  Version  3.0 Page 74 of 74 
 
 
                                                   Medtronic Business Restricted    056-F275, vB Clinical Investigation Plan Template  19. Version History  
Version  Summary of changes  Author(s)/Title  
1.0 • Not Applicable, New Document   Pr. CRS  
2.0 Amendment 1 i ncludes the following updates and 
clarifications:  
a. patients using cannabinoids (including cannabidiol) 
are excluded from the study  
b. patients must be on a minimum daily systemic opi[INVESTIGATOR_40533] > [ADDRESS_1242317] of care  Pr. CRS  
3.0 Amendment 2 includes the following updates:  
• Transitioned to 056- F275 CIP template vB  
• Updated language on study follo w-up duration  to 
include study exit at 6 months throughout  (removal 
of 9 Month and 12 Month visits)  
•  
 
• Entered final enrollment number of 93 subjects throughout  
• Inserted Section 8 : Study Site Requirements in 
alignment with  new CIP Template  
• Updated se ction 10.5 (Post -Op) to include “Initial and 
Final device interrogation reports” missed under V2.0  
• Updated section 10.1, Table 2, section 10.7, and  
section 10.11 (Table 3) to remove reference to 9 and 12 month visits  
• 
 
• Updated language in section 14.1.[ADDRESS_1242318] the non -inferiority  margin for VAS from 1 to 
10 and to clarify sample size  calculations  
• Updated section references throughout CIP Sr. CRS  
 
